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Duranske: Reforming Regenerative Medicine Regulation

REFORMING REGENERATIVE MEDICINE
REGULATION
Sarah Duranske*
INTRODUCTION
The gods were angry. Prometheus and his brother had endowed the
creatures of the earth with gifts to help them survive and prosper:
speed, cunning, strength. But, in error, Prometheus had overlooked
man—a naked and weak creature that would surely perish unless
gifted with something truly remarkable. So, Prometheus snuck onto
Mount Olympus and stole fire from the gods. This gift he provided to
man. But the gods disapproved—with fire, man could challenge their
superiority. As punishment, Prometheus was chained to a rock. Each
day, an eagle tore apart and devoured part of his liver. Each night, the
liver regrew, ensuring that his torture would be unending.1
Thus begins the story of regenerative medicine.
When humans are wounded, our bodies heal through a mixture of
scar tissue formation and tissue regeneration.2 We are familiar with
scar tissue formation—special cells migrate to the site of the injury
and produce proteins that support the tissue.3 But we have another
wound-healing ability demonstrated by Prometheus—the ability of
some cells to divide to produce more of themselves.4 In humans, the
*

Thomas C. Grey Fellow and Lecturer at Law, Stanford Law School. I wish to thank Hank T. Greely,
Michelle M. Mello, Norman Spaulding, W. Nicholson Price II, Yanbai Andrea Yang, Rebecca Wolitz,
Alix Rogers, Ji Seon Song, and the participants of the 2017 Grey Fellows Forum for their invaluable
comments.
1. Mark Cartwright, Prometheus, ANCIENT HIST. ENCYCLOPEDIA (Apr. 20, 2013),
https://www.ancient.eu/Prometheus/ [https://perma.cc/KRM7-HX58].
2. See Nat’l Insts. of Health, Regenerative Medicine, RES. PORTFOLIO ONLINE REPORTING TOOLS,
https://report.nih.gov/NIHfactsheets/ViewFactSheet.aspx?csid=62&key=R|[num]|R [https://perma.cc/A
7BM-7SJW] (last updated Oct. 2010) [hereinafter NIH Fact Sheets: Regenerative Medicine]; Univ. of
Ill. at Chi., Mechanism that Limits Scar Formation Discovered, SCIENCEDAILY (June 11, 2010),
https://www.sciencedaily.com/releases/2010/06/100610154459.htm [https://perma.cc/5LKX-AQW9].
3. Juan Diego Naranjo et al., Regenerative Medicine: Lessons from Mother Nature, 11
REGENERATIVE MED. 767, 768 (2016); Univ. of Ill. at Chi., supra note 2.
4. SCOTT F. GILBERT, DEVELOPMENTAL BIOLOGY, ch. 18 (6th ed., 2000) (ebook),
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natural ability to regenerate tissue is limited. Only a few specific
tissues such as bone marrow, liver, and the outer layer of skin
demonstrate this ability.5
The ability to regenerate tissue is even more amazing in other
species. The axolotl is a Mexican salamander known for its ability to
regenerate lost limbs. The axolotl regenerates tissues in a way that
humans cannot: the cells near the site of the injury lose their
specialization and then morph into the cells needed to regrow the
missing limb.6
The salamander’s regenerative abilities inspired scientists. Could
the same mechanism work in humans? In early experiments,
scientists harvested stem cells from tissues in the human body and
inserted the cells into an injury site.7 Because stem cells retain the
ability to multiply (called “proliferation”) and turn into different cell
types (called “differentiation”), scientists hoped that the stem cells
would cause the creation of new tissues. The results, however, were
“disappointing at best.”8 The interactions between stem cells, the
microenvironment, the disease state, and dosing concerns stymied
early efforts to create functional tissue.9
But early experiments have progressed into increasingly successful
applications.10 Today, some regenerative medicine therapies are
commercially available, with others at various stages in the research
pipeline.11 And the field is broader than just stem cell therapies.
Regenerative medicine is defined as the branch of medicine that
develops methods to regrow, repair, or replace damaged or diseased

https://www.ncbi.nlm.nih.gov/books/NBK9971/ [https://perma.cc/TX9T-NRD2]; Naranjo, supra note 3,
at 767.
5. Ricardo Londono & Stephen F. Badylak, Biologic Scaffolds for Regenerative Medicine:
Mechanisms of In vivo Remodeling, 43 ANNALS OF BIOMEDICAL ENGINEERING 577, 582 (2014).
6. GILBERT, supra note 4; Naranjo, supra note 3, at 769.
7. ANGELO S. MAO & DAVID J. MOONEY, Regenerative Medicine: Current Therapies and Future
Directions, 112 PNAS 14452, 14452 (2015), http://www.pnas.org/content/112/47/14452
[https://perma.cc/J6RC-2EHT].
8. Naranjo, supra note 3, at 770.
9. Id.
10. Id.
11. MAO & MOONEY, supra note 7, at 14452; NIH Fact Sheets: Regenerative Medicine, supra
note 2.
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cells or tissues. 12 It includes a variety of approaches, such as
transplanting cells to promote healing, editing genes in cells to attack
cancer, and even building organs from biological materials.13
Regulating regenerative medicine therapies is no easy task.
Finding a balance between competing interests–enabling timely
access for needy patients while simultaneously ensuring a positive
benefit/risk profile and promoting the development of beneficial
innovations–is hard enough at any given point in time. But add in
constantly advancing scientific knowledge and increasing
commercialization opportunities, and the regulatory system struggles
to keep pace.
As new potential therapies have emerged and challenged the
existing regulatory structure, stakeholders have prodded Congress
and the Food and Drug Administration (FDA) for reforms to make
the pathway to the marketplace less rigorous.14 These efforts include
enacted laws, such as a regenerative medicine provision in the 21st
Century Cures Act, congressional bills that have been introduced but
died, and policy whitepapers. But others oppose loosening the
regulatory framework and argue that the current level of premarket
testing for safety and efficacy is needed both to ensure public health
and to advance the field of regenerative medicine by generating
important clinical data.15 Still others advocate for a middle path that
advances some therapies while protecting the public from the most
egregious risks.16 I evaluate these reform proposals based on the dual
goals of regulating medical products based on risk: protecting the
public by limiting access to therapies where the risks outweigh the
benefits, and promoting innovations that improve public health.

12. See NIH Fact Sheets: Regenerative Medicine, supra note 2.
13. Naranjo, supra note 3, at 772.
14. See Maude L. Cuchiara, Jackie K. Olive & Kirstin Matthews, Regulating the Therapeutic
Translation of Regenerative Medicine, 15 EXPERT OPINION ON BIOLOGICAL THERAPY 1387, 1388
(2015), http://www.tandfonline.com/doi/full/10.1517/14712598.2015.1064895 [https://perma.cc/2C2XVM3M].; Robin Downey & Rose Geransar, Stem Cell Research, Publics’ and Stakeholder Views, 16
HEALTH L. REV. 69, 69 (2008).
15. Dina Gould Halme & David A. Kessler, FDA Regulation of Stem-Cell–Based Therapies, 355
NEW ENG. J. MED. 1730, 1730 (2006).
16. Cuchiara, Olive & Matthews, supra note 14, at 1388–89.
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I first argue that proposals to speed FDA approval through
adaptive licensing are premature. These proposals, which differ in the
details but share the same core features, would have the FDA
approve regenerative medicine therapies based on less robust clinical
evidence of safety and efficacy, but restrict the initial patient
population and impose post-marketing obligations on the sponsor to
gather evidence of the product’s safety and efficacy in “real world”
conditions. Although adaptive licensing’s goals of accelerating
access to therapies and generating real world evidence are
sympathetic, the proposals are premature. Applying a theoretical
framework of adaptive management that identifies appropriate
conditions for iterative regulation highlights the fatal problem with
adaptive licensing for regenerative medicine therapies: the risk of
patient harm is too high. Existing evidence from other medical
products approved under expedited pathways is instructive: it
demonstrates that the third and final phase of clinical trials is vital to
determine the safety and efficacy of a medical product, and that
products approved under expedited pathways have more safety
problems than those approved under the traditional process.
Second, I consider reform proposals for low and moderate-risk
regenerative medicine therapies. Based on recent scientific literature,
I argue that the current laws and regulations set an appropriate
framework for the regulation of regenerative medicine therapies and
support incremental reforms.
This current climate of reform creates an opportunity to analyze
the success of the current regime in furthering the dual goals of
medical product regulation: protecting public health and encouraging
beneficial innovations. It invites us to consider whether other
frameworks can better resolve the tension between the short-term
goals of enabling access to therapies for needy patients with the
longer-term goals of advancing society’s understanding of the
science and medicine of regenerative therapies.
Health law scholars writing on regenerative medicine have largely
ignored the broader questions raised by the current reform climate
and have focused instead on the legal and normative issues raised in a

https://readingroom.law.gsu.edu/gsulr/vol34/iss3/3

4

Duranske: Reforming Regenerative Medicine Regulation

2018]

REFORMING REGENERATIVE MEDICINE REGULATION

635

2014 case regarding the authority of the FDA to regulate a subsection
of therapies that use a patient’s own cells as source materials.17 In
that regard, this Article makes a unique contribution to the literature
by using theories of risk regulation to evaluate the current structure
and proposed reforms. In doing so, I seek to offer a considered and
thorough legal and normative analysis of the existing regulatory
framework and reform proposals that can meaningfully inform the
policy debate.
This Article has four parts. Part I describes the regenerative
medicine industry and the existing federal regulatory structure that
governs regenerative medicine therapies. Part II addresses the need
for regulation as well as the critiques of the current framework. Part
III analyzes proposals for progressive licensing of higher-risk
regenerative medicine therapies regulated as biologics. Part IV
evaluates reforms for regenerative medicine therapies regulated as
human cell and tissue products.
I. Regulating Regenerative Medicine
Scores of regenerative medicine products using regular cells from
the human body (called “somatic” cells) are commercially available,
and hundreds of clinical trials are investigating stem cell therapies.18
Yet the fact that only one type of stem cell product has received FDA
approval has motivated some industry representatives and patient
advocates to call for reforms to speed regenerative medicine products
to market. The existing multi-tiered regulatory structure, however,
already allows for tailored regulation depending on a therapy’s risk
of harm, and such tailoring includes less burdensome pathways to
17. However, two important exceptions exist. See generally Barbara von Tigerstrom, Revising the
Regulation of Stem Cell Based Therapies: Critical Assessment of Potential Models, 70 FOOD & DRUG
L.J. 315 (2015) (examining exemptions from regulation in Australia and the European Union); see also
Margaret Foster Riley, Twenty-First-Century Technology with Twentieth-Century Baggage: FDA
Regulation of Regenerative Medicine, in FDA IN THE 21ST CENTURY: THE CHALLENGES OF
REGULATING DRUGS AND NEW TECHNOLOGIES 455, 466 (I. Glenn Cohen & Holly F. Lynch, eds., 2015)
(noting that altering the minimal manipulation and homologous use standards may speed access to
regenerative medicine therapies).
18. MAO & MOONEY, supra note 7, at 14452; see generally Clinicaltrials.gov, U.S. NAT’L LIBRARY
OF MED., https://clinicaltrials.gov/ [https://perma.cc/YC38-82HD] (last visited Jan. 6, 2018) (providing
“a database of privately and publicly funded clinical studies conducted around the world”).
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market for lower-risk therapies. In this section, I describe the state of
the regenerative medicine industry and the harms the therapies can
cause. I then explain the current regulatory structure and its critiques.
A. The State of the Industry
Regenerative medicine therapies seek to harness the body’s ability
to heal itself. Stem cell therapies epitomize regenerative medicine
therapies because of their potential to heal and to harm. The potential
of stem cells to regrow, repair, or replace damaged or diseased cells,
organs, or tissues motivated early researchers and continues to excite
today.19 Thousands of stem cell trials have been completed, and
many hundreds more are ongoing.20 In these trials, investigators
study how new combinations of stem cell products and delivery
mechanisms affect a range of diseases and conditions.21 Yet, in spite
of this progress, the FDA has approved only one type of stem cell
product: hematopoietic (blood forming) stem cells from cord blood to
reconstitute a patient’s blood and immune system after myeloablative
treatments like radiation.22
19. Erin Allday, ‘Super exciting’ Results in Stem Cell Therapy Trial, SFGATE (Oct. 2, 2017,
9:09AM), http://www.sfgate.com/health/article/Super-exciting-results-in-stem-cell-therapy12245199.php [https://perma.cc/6YG3-7HA5] (reporting on Asterias Biotherapeutics’ Phase 1/2 clinical
trial results which demonstrated that four out of six paralyzed patients receiving a stem-cell derived
injection showed improvement in motor levels); Asterias Announces Two Significant Developments for
Spinal Cord Injury Program, ASTERIAS BIOTHERAPEUTICS (Oct. 2, 2017),
http://www.asteriasbiotherapeutics.com/inv_news_releasre_text.php?releaseid=2303887&date=October
+02%2C+2017&title=Asterias+Announces+Two+Significant+Developments+for+Spinal+Cord+Injury
+Program [https://perma.cc/29N7-RT2T].
20. See Clinicaltrials.gov, supra note 18 (searching the term “stem cell,” limited to recruiting,
enrolling, and active interventional (or clinical) trials returned 1,518 results, and the same search for
completed trials returned 1,746 results).
21. One well-publicized trial transplanted autologous iPSC-derived retinal cells to treat age-related
macular degeneration. Erin Kimbrel & Robert Lanza, Pluripotent Stem Cells: The Last 10 Years, 11
REGENERATIVE. MED. 831, 834–36 (2016). The transplant into the first patient went well, but the trial
was suspended before transplant into the second patient because the sample was found to contain a
genetic mutation that could increase the risk that the patient would develop cancer from the transplant.
Id. Separately, a Phase 1 trial tested the safety and feasibility of human embryonic stem cell-derived
cardiac progenitor cells embedded onto a patch. Id. The patch was then embedded into the heart during
surgery. Id. This clinical trial was based on preclinical evidence that the cells engrafted and then
differentiated into cardiac muscle cells in preclinical models. Id. Another trial is planned to study the
safety and effectiveness of a drug delivery device implanted under the skin that releases human
embryonic stem cell-derived pancreas cells to treat type I diabetes. Id.
22. The product Hemacord provides hematopoietic (blood-forming) stem cells from a donor’s
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Excitement over stem cells has also led to the exploitation of
desperate patients. Stem cell clinics offer unproven and unregulated
stem cell treatments to cure a variety of ailments, so long as a patient
can pay the out-of-pocket costs. In a 2016 study, Professors Paul
Knoepfler and Leigh Turner identified 351 businesses engaged in
direct-to-consumer marketing of stem cell interventions at 570
clinics.23 The majority of these businesses marketed autologous
interventions, where the stem cells used for treatment came from the
patients’ own tissues.24 The most common source for the autologous
stem cells was adipose (fat) tissue, followed by bone marrow. Stem
cell clinics promote their treatments for a variety of diseases and
conditions, ranging from autism and Alzheimer’s disease to sports
injuries and cosmetic surgery.25 The cost of treatment can range from
$5,000 to $20,000.26
Although stem cell-based therapies have garnered much attention,
therapies that use other cell and tissue sources also fall under the
rubric of regenerative medicine therapies.27 Several products that use
somatic cells or cell-derivatives are commercially available. For
example, Carticel, an FDA-approved product to treat articular
cartilage defects (injuries to the slick cartilage at knee joints and
other joints), uses chondrocytes (the cell type in healthy cartilage)
harvested from the patient’s cartilage, expanded in a lab, and reinserted at the site of injury.28 The cosmetic product laViv uses
allogeneic cord blood to reconstitute the patient’s blood and immune systems after myeloablative
treatment (such as radiation). MAO & MOONEY, supra note 7, at 14452; Approved Cellular and Gene
Therapy Products, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProAppro/
[https://perma.cc/DJ5H-FE44] (last updated Sept. 20, 2017). Similar transplants occur using stem cells
from a donor’s own cord blood. See Kang-Hsi Wu et al., Letter to the Editor: Autologous Cord Blood
Transplantation in a Child with Stage 4 Neuroblastoma, 48 BONE MARROW TRANSPLANTATION 317,
318 (2013).
23. Leigh Turner & Paul Knoepfler, Selling Stem Cells in the USA: Assessing the Direct-toConsumer Industry, 19 CELL STEM CELL 154, 154 (2016).
24. Id. at 155.
25. Id. at 155–56.
26. Usha Lee McFarling, FDA Weighs Crackdown that Could Shut Hundreds of Stem Cell Clinics,
STAT (Sept. 9, 2016), https://www.statnews.com/2016/09/09/stem-cell-fdahearing/ [https://perma.cc/E8GU-HHGW].
27. MAO & MOONEY, supra note 7, at 14452.
28. Id.
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autologous fibroblasts (the main cell found in connective tissue,
sourced from the patient) to improve the appearance of nasolabial
fold wrinkles in adults.29 The product Apligraf uses human foreskin
fibroblasts to create wound-healing grafts.30
Rounding out the major types of regenerative medicine therapies
are gene editing products and bioengineering products. The FDA
approved the first gene therapy in the United States in August 2017.31
Kymriah, a cell-based CAR-T gene therapy from Novartis, is created
from a patient’s own T-cells.32 The patient’s T-cells are collected and
then genetically modified to include a new gene.33 When the cells are
infused back into the patient, the modified gene causes the cell to
target and kill certain leukemia cells.34 Other gene therapies remain
in the research pipeline. A large number of gene editing trials modify
the genes in T-cells to alter their susceptibility to autoimmune
viruses, like HIV, or to enhance their ability to recognize and bind to
diseased cells.35
Researchers are also working to manufacture human tissue, even
entire organs. Bioengineering, or tissue engineering, is the process of
creating cell-based products for the structural repair of various tissue
defects.36 At the Wake Forest Institute for Regenerative Medicine,
Dr. Anthony Atala has tested 3-D printing technology that has
printed cartilage, bone, and muscle tissue that was then successfully
implanted into rodents.37 Dr. Laura Niklason has commenced a Phase
29. Id. at 14452–53.
30. Id.
31. Press Release, U.S. Food & Drug Admin., FDA Approval Brings First Gene Therapy to the
United States (Aug. 30, 2017),
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm
[https://perma.cc/D6X2-CBHW].
32. In Historic First, FDA Approves Gene Therapy for Acute Lymphoblastic Leukemia, MANAGED
CARE (Aug. 30, 2017), https://www.managedcaremag.com/news/historic-first-fda-approves-genetherapy-acute-lymphoblastic-leukemia [https://perma.cc/68DZ-7TEH].
33. Id.
34. Id.
35. Kuang-Yui Chen & Paul S. Knoepfler, To CRISPR and Beyond: The Evolution of Genome
Editing in Stem Cells, 11 REGENERATIVE MED. 801, 809 (2016).
36. The Comm. for Advanced Therapies (CAT) & The CAT Sci. Secretariat, Challenges with
Advanced Therapy Medicinal Products and How to Meet Them, Perspectives, 9 NATURE REVS. 195,
196 (2010).
37. Mathew Shaer, Need a New Organ? Surgeon Anthony Atala Sees a Future Where You Can
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3 clinical trial testing bioengineered blood vessels grown from
human cells that are seeded into a biodegradable scaffold, and given
nutrients and mechanical signals to coax them to grow into a new
blood vessel.38
B. Regulatory Framework
As the primary agency in the United States regulating medical
products, the FDA is tasked with ensuring the safety and efficacy of
regenerative medicine therapies. It regulates these therapies based on
three goals: (1) to prevent the use of contaminated cells and tissues
with the potential for transmitting infectious diseases including AIDS
and hepatitis; (2) to prevent improper handling that might
contaminate or damage cells and tissues; and (3) to ensure that
clinical safety and effectiveness is demonstrated for cells and tissues
that are highly processed, are used for atypical functions, are
combined with non-tissue components, or are used for metabolic
purposes.39
Prior to 1997, federal regulation of cell and tissue products was
fragmented. The FDA viewed organ and tissue transplants as simply
part of the practice of medicine.40 Because the FDA does not regulate
the practice of medicine, but instead has jurisdiction over the tools
used by doctors in the practice of medicine, it declined to assert
authority over tissue transplants.41 But two trends started to blur the
line between the practice of medicine and the FDA’s jurisdiction:
first, technological advances allowed for the storing, transporting,
Simply Print It Out, SMITHSONIAN MAG. (Dec. 2016), http://www.smithsonianmag.com/innovation/mira
cle-maker-anthony-atala-winner-smithsonian-ingenuity-awards-2016-life-sciences-180961121/
[https://perma.cc/R4Y8-4EVV].
38. 37: Humacyte, CNBC (June 7, 2016, 6:03 AM), http://www.cnbc.com/2016/06/06/humacyte2016-disruptor-50.html [https://perma.cc/7GQM-2S63].
39. Martha A. Wells, Overview of FDA Regulation of Human Cellular and Tissue-Based Products,
52 FOOD & DRUG L.J. 401, 406 (1997).
40. Frank A. Duckworth, Regulation of Human Tissues and Organs, 46 FOOD DRUG COSMETIC L.J.
1, 12 (1991).
41. Id. But see Patricia J. Zettler, Toward Coherent Federal Oversight of Medicine, 52 SAN DIEGO L.
REV. 427, 427–28 (2015) (arguing that, contrary to the conventional wisdom that states regulate medical
practice while the federal government regulates medical products, the federal government does—and
should—regulate medical practice when public health is affected).
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and preserving of organs and tissues, which added new variables to
transplant procedures; and second, the AIDS crisis heightened the
consequences of communicable disease transmission.42
Thus, in 1997, the FDA proposed its current approach to
regulation for articles “containing or consisting of human cells or
tissues that are intended for implantation, transplantation, infusion, or
transfer into a human recipient.”43 The regulatory regime was
designed to “improve the protection of the public health without
imposing unnecessary restrictions on research, development, or the
availability of new products.”44 The FDA delineated three levels of
regulation for human cell and tissue products based on the product’s
risk-level: (1) products not subject to regulation; (2) products
regulated as human cell, tissues, or cellular- or tissue-based products
(“cell or tissue products”) under Section 361 of the Public Health
Service Act (PHSA); and (3) products regulated as biological drugs
under Section 351 of the PHSA.45 The FDA’s current solution is
therefore a three-tiered framework based on a therapy’s risks of
communicable disease, safety, and effectiveness.46 This section
provides an overview of the framework from the lowest level of
regulation to the highest.
1. Same Surgical Procedure Exemption
The lowest tier of regulation is no regulation. The FDA does not
regulate cells and tissues that are removed from a patient and
transplanted back into that patient during a single surgical
procedure.47 The FDA reasoned that the communicable disease risks,
as well as safety and effectiveness risks, from these procedures
would be no different than those typically associated with surgery.48
42. Duckworth, supra note 40.
43. 21 C.F.R. § 1271.3(d) (2017).
44. Human Cells, Tissues, and Cellular and Tissue-Based Products, 66 Fed. Reg. 5447 (Jan. 19,
2001) (codified at 21 C.F.R. pts 207, 807, 1271).
45. Wells, supra note 39, at 406.
46. Id. The current three-tiered system was introduced in 1997, with the final rule becoming
effective in 2005. Id.
47. 21 C.F.R. § 1271.15(b) (2017).
48. 21 C.F.R. § 1271.3(d); U.S. FOOD & DRUG ADMIN., DOC. NO. 97N-0068, PROPOSED APPROACH
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And, because surgery is part of the practice of medicine, and
therefore generally regulated by the state and not the federal
government, the FDA exempted these procedures from its rules.49
For policy reasons, the FDA also excludes cells or tissues removed
from a donor and immediately transferred to an intimate sexual
partner.50
Some articles are not covered in the FDA’s human cell and tissue
regulatory scheme because they are covered by other regulations.51
These include whole organs; minimally manipulated bone marrow;
blood products such as whole blood, platelets, and plasma; and
extracts such as human milk, collagen, and growth factors.52
2. Section 361 Products
The FDA implemented an intermediate tier of regulation for cell or
tissue products between 1997 and 2005. The thrust of the new rules
was to address those products whose main risk to public health and
safety was the transmission of communicable diseases. The rules
were promulgated under the authority of section 361 of the PHSA,
which provides jurisdiction for “regulations . . . necessary to prevent
the introduction, transmission, or spread of communicable
diseases . . . .”53
Only those cell or tissue products that meet four criteria qualify as
“section 361” products under this intermediate tier of regulation.
First, the product can be no more than minimally manipulated.54 This
means that the product cannot be processed in a manner that alters

REGULATION OF CELLULAR AND TISSUE-BASED PRODUCTS 12 (1997) [hereinafter PROPOSED
APPROACH TO REGULATION OF CELLULAR AND TISSUE-BASED PRODUCTS].
49. See, e.g., Zettler, supra note 41, at 436–37, 482–93.
50. 21 C.F.R. § 1271.15(e); see also PROPOSED APPROACH TO REGULATION OF CELLULAR AND
TISSUE-BASED PRODUCTS, supra note 48, at 13.
51. 21 C.F.R. § 1271.3(d)(1–8).
52. Id.
53. 42 U.S.C. § 264(a) (2012).
54. James R. Ravitz, Naomi J. L. Halpern & Emily M. Leongini, FDA Announces “New”
Framework to Regulate Stem Cell Therapies and Regenerative Medicine, LEXOLOGY (Sept. 8, 2017),
https://www.lexology.com/library/detail.aspx?g=bb78fe6e-1cdd-499a-907d-087ebb5fc28f
[https://perma.cc/Q7N3-FX8Q].
TO
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the cells’ or tissues’ relevant characteristics.55 Second, the product
must be intended for homologous use, which means that the cells or
tissues must perform the same basic function in the recipient as in the
donor.56 Third, the product’s manufacturer must not combine the
cells or tissues with any other article except for “water, crystalloids,
or a sterilizing, preserving, or storage agent, provided that the
addition of water, crystalloids, or the sterilizing, preserving or storage
agent does not raise any new clinical safety concerns with respect to
the [cell or tissue product].”57 Fourth, the product must either (a) not
have a systemic effect and not be dependent on the metabolic activity
of living cells for its primary function, or (b) if it does have a
systemic effect or is dependent upon the metabolic activity of living
cells for its primary function, it must be for autologous use, for
allogeneic use in a close relative, or for reproductive use.58
The obligations for establishments that manufacture section 361
products are relatively light compared to those for biologics
manufacturers. The establishments must register with the FDA;
follow procedures for testing, screening, and determining donor
eligibility; and follow current Good Tissue Practices to prevent the
introduction, transmission, or spread of communicable disease.59
3. Biologics/Drugs
If a regenerative medicine product does not meet either the same
surgical procedure exemption or the requirements of section 361,
then the product is regulated as a biologic under section 351 of the
Public Health Service Act.60 Section 351 covers biological products,
55. U.S. FOOD & DRUG ADMIN., MINIMAL MANIPULATION OF HUMAN CELLS, TISSUES, AND
CELLULAR AND TISSUE-BASED PRODUCTS: DRAFT GUIDANCE FOR INDUSTRY AND FOOD
AND DRUG ADMINISTRATION STAFF 2 (2014) [hereinafter FDA DRAFT GUIDANCE ON MINIMAL
MANIPULATION].
56. U.S. FOOD & DRUG ADMIN., HOMOLOGOUS USE OF HUMAN CELLS, TISSUES, AND CELLULAR
AND TISSUE-BASED PRODUCTS: DRAFT GUIDANCE FOR INDUSTRY AND FDA STAFF (2015) [hereinafter
FDA DRAFT GUIDANCE ON HOMOLOGOUS USE].
57. 21 C.F.R. § 1271.10(a)(3) (2004).
58. Id. § 1271.10.
59. Id. § 1271.1(a).
60. 42 U.S.C. § 262 (Supp. 2017). A limited number of cell or tissue products are regulated as
medical devices, but because the majority of cell or tissue products are biologics or human cell or tissue
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including blood-derived products and products containing cells or
microorganisms.61 The FDA considers biological products a subset of
drugs, so the FDA’s drug regulations also apply to section 351
products.62 Thus, the term “drug” is used in this article to cover
biologic products as well. If a biologic is licensed under section 351,
it does not need to be separately licensed as a new drug.63
Biological products must receive a license before they can be
introduced into interstate commerce.64 The biologics license
application must demonstrate that the biological product is safe, pure,
and potent, and that the facility in which it is manufactured meets
standards designed to ensure the product’s continued safety, purity,
and potency.65 Like a new drug application, a biologics license
application usually requires data from preclinical or clinical trials.66
In order to initiate a clinical trial, the biologic’s sponsor must submit
an Investigational New Drug application before proceeding with the
clinical trial.67
The clinical study definitions for biologics are identical to those
for new drugs.68 As such, biologics regulated under section 351
generally go through three phases of clinical trials unless they follow
an expedited path. The typical path to approval starts with a small
(twenty to eighty patients) phase 1 clinical trial designed to evaluate
safety and the product’s mechanism of action.69 Phase 2 trials are
products, a thorough examination of the medical device scheme is outside the scope of this article.
61. Id.; U.S. FOOD & DRUG ADMIN., Frequently Asked Questions About Therapeutic Biological
Products,
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Appro
valApplications/TherapeuticBiologicApplications/ucm113522.htm. [https://perma.cc/FP7B-EKLD] (last
updated July 7, 2015).
62. U.S. FOOD & DRUG ADMIN., supra note 61.
63. 42 U.S.C. § 262(j).
64. Id. § 262(a)(1).
65. Id. § 262(a)(2)(C)(i).
66. 21 C.F.R. § 601.2(a) (2016); U.S. FOOD & DRUG ADMIN., APPLICATION TO MARKET A NEW OR
ABBREVIATED NEW DRUG OR BIOLOGIC FOR HUMAN USE (2017)
https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/ucm082348.pdf
[https://perma.cc/J4QP-A89J].
67. See U.S. FOOD & DRUG ADMIN., supra note 61.
68. 21 C.F.R. § 312.2(a) (2009) (“Except as provided in this section, this part applies to all clinical
investigations of products that are subject to section 505 of the Federal Food, Drug, and Cosmetic Act
[New Drugs] or to the licensing provisions of the Public Health Service Act.”).
69. Id. § 312.21(a).
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designed to evaluate the effectiveness of a drug and to determine
common short-term side effects and risks.70 Phase 2 studies usually
involve no more than several hundred patients. Large-scale phase 3
studies gather sufficient data on the product’s safety and efficacy to
support extrapolating the results to the general population.71 In
addition to the clinical data, a biologics license application also must
contain a significant amount of information about the manufacturing
process, operating procedures, and equipment used in the product’s
manufacture.72
Approved biologics must adhere to current good manufacturing
requirements.73 These detailed and comprehensive requirements
address many aspects of the manufacturing process, personnel
qualifications, equipment validation, standard operating procedures,
quality control processes, change and document controls, packaging
and labeling, purchasing controls, acceptance activities, and record
keeping.74 The manufacturers are also required to notify the FDA of
certain changes in manufacturing and of adverse events.75
C. A Lifecycle Approach
The FDA approves a new drug or biologic for marketing based on
the pretrial and clinical trial evidence submitted by the sponsor.76
This traditional approval paradigm has two drastically distinct stages:
pre-approval and post-approval.77 Before a product is approved, the
only patients who may access it are those in a clinical trial who have
given informed consent.78 But after the FDA approves a biologic, it
70. Id. § 312.21(b).
71. Id. § 312.21(c).
72. Id. § 601.2(a).
73. Facts About the Current Good Manufacturing Practices (CGMPs), U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/drugs/developmentapprovalprocess/manufacturing/ucm169105.htm
[https://perma.cc/S2LF-7YRV] (last visited Oct. 6, 2017).
74. 21 C.F.R. §§ 211, 601, & 820 (2017).
75. Id. § 314.80 (2017) (reporting for drugs); id. § 600.80 (2010) (reporting for biologics);
id. § 601.12 (2012) (reporting requirements).
76. Rebecca Eisenberg, The Role of the FDA in Innovation Policy, 13 MICH. TELECOMM. & TECH.
L. REV. 366, 370 (2007).
77. Hans-Georg Eichler et al., Adaptive Licensing: Taking the Next Step in the Evolution of Drug
Approval, 91 CLINICAL PHARMACOLOGY & THERAPEUTICS 426, 426 (2012).
78. Id.
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generally becomes widely available.79 In the most common scenario,
patients can access the biologic without any particular eligibility
requirements, and may even obtain it for unapproved conditions
through an off-label prescription.80
This traditional approval paradigm has suffered extensive
criticism, because relying on pre-market evidence alone fails to give
an accurate picture of a medical product’s risks and benefits.81
Clinical trials are designed with narrow and specific inclusion
criteria, but post approval use includes patients with different risk
factors such as age, medication use, and chronic conditions.82
Indications for use in clinical trials are specific and well-monitored,
but indications for use in the marketplace can be off-label and
untested in clinical trials.83 And because clinical trials are relatively
short, they can fail to reveal the long-term risks or effects of the
product.84
In response, Congress and the FDA have begun shifting towards a
lifecycle approach to drug evaluation where risks and benefits are
monitored throughout a drug’s lifecycle, including after approval.85
This approach is reflected in the FDA’s programs that expedite
approval of new drugs with an accompanying commitment from the
sponsor to provide postmarket evidence of safety and effectiveness.
For regenerative medicine therapies, the 21st Century Cures Act
created an accelerated approval pathway for “regenerative medicine
advanced therapies” (RMAT).86 To qualify as an RMAT, a therapy
79. Id.
80. Id.
81. Shannon Gibson & Trudo Lemmens, Overcoming “Premarket Syndrome,” in FDA IN THE 21ST
CENTURY: THE CHALLENGES OF REGULATING DRUGS AND NEW TECHNOLOGIES 269, 269 (I. Glenn
Cohen & Holly F. Lynch, eds., 2015) [hereinafter Overcoming Premarket Syndrome]; Charles
Steenburg, The Food and Drug Administration’s Use of Postmarketing (Phase IV) Study Requirements:
Exception to the Rule?, 61 FOOD & DRUG L.J. 295, 297 (2006) (discussing the shortcomings of
premarket clinical trials).
82. U.S. FOOD & DRUG ADMIN., STRUCTURED APPROACH TO BENEFIT-RISK ASSESSMENT IN DRUG
REGULATORY DECISION-MAKING: DRAFT PDUFA V IMPLEMENTATION PLAN 9 (2013).
83. Margaret Foster Riley, An Unfulfilled Promise: Changes Needed to the Drug Approval Process
to Make Personalized Medicine a Reality, 70 FOOD & DRUG L.J. 289, 297 (2016).
84. Eisenberg, supra note 76, at 376.
85. Overcoming Premarket Syndrome, supra note 81, at 269; Eisenberg, supra note 76, at 376; U.S.
FOOD & DRUG ADMIN., supra note 82, at 9.
86. 21st Century Cures Act, sec. 3033, 130 Stat. 1101 (2016) (codified at 21 U.S.C. § 356).
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must first meet the statutory definition of a regenerative medicine
therapy, defined to include “cell therapy, therapeutic tissue
engineering products, human cell and tissue products, and
combination products using any such therapies or products, except
for those regulated solely under section 361 of the Public Health
Service Act and part 1271 of title 21, Code of Federal Regulations.”87
Thus, foundationally, this section only addresses those products that
are not regulated as section 361 products. The therapy must also be
intended to treat, modify, reverse, or cure a serious or life-threatening
disease or condition,88 and be supported by “preliminary clinical
evidence” that indicates that the therapy has the potential to address
unmet medical needs for the disease or condition.89 The FDA has
begun implementing this provision and, as of July 2017, had
approved four requests to qualify products under the section.90
An RMAT is entitled to the same benefits for expedited
development and review as drugs that receive Breakthrough Therapy
designation are,91 including interactions with the FDA throughout the
development process, advice to ensure that the development program
for obtaining nonclinical and clinical data is efficient, and helping to
ensure that clinical trial design is as efficient as practicable.92
In addition, a therapy designated as an RMAT may be eligible for
Priority Review and Accelerated Approval.93 This means that an
RMAT may receive approval based on surrogate or intermediate
endpoints “reasonably likely to predict long-term clinical benefit,” or
on data obtained from a “meaningful number of sites, including
through expansion to additional sites.”94
87. The Act does not cover section 361 products, but covers only those products otherwise regulated
as a drug or biologic. 21 U.S.C. § 356(g)(8) (Supp. 2016).
88. 21 U.S.C. § 356(g)(2)(B).
89. Id. § 356(g)(2)(C).
90. Scott Gottlieb, How FDA Plans to Help Consumers Capitalize on Advances in Science, U.S.
FOOD & DRUG ADMIN., FDA VOICE (July 7, 2017),
https://blogs.fda.gov/fdavoice/index.php/2017/07/how-fda-plans-to-help-consumers-capitalize-onadvances-in-science/ [https://perma.cc/2D6Y-X73Y].
91. 21 U.S.C. § 356(g)(1); see id. § 356(a)(3)(B).
92. Id. § 356(a)(3)(B).
93. Id. §§ 356(c), 356(g)(6)(B).
94. Id. §§ 356(c), 356(g)(6)(B).
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The RMAT approval pathway is the same as the Accelerated
Approval pathway for drugs in most regards, but the Accelerated
Approval pathway does not contain the option of approval based on
data from “a meaningful number of sites.”95 This may reflect a
liberalization of acceptable forms of scientific evidence based on the
promise of research using electronic health records.96
A second difference is that RMATs that are approved under the
accelerated pathway are subject to postapproval requirements and
may meet such obligations “as appropriate” by submitting clinical
evidence, clinical studies, patient registries, or “other sources of real
world evidence, such as electronic health records”; by collecting
larger confirmatory data sets; or by monitoring patients treated with
the therapy prior to its approval.97 This is a larger category of
postapproval options than is available under the Accelerated
Approval pathway, where the sole postapproval requirement option is
that the “sponsor conduct appropriate postapproval studies to verify
and describe the predicted effect on irreversible morbidity or
mortality or other clinical benefit.”98
FDA officials have acknowledged both the benefits and limitations
of using real world evidence. In a 2016 New England Journal of
Medicine article authored by fifteen top FDA officials, the officials
observed that the definition of “real world evidence” encompasses
data from randomized trials conducted in a real-world setting, so
viewing “real-world evidence” and “randomized trials” as mutually
exclusive is incorrect.99 But concerns about the quality of real world
evidence, and the limitations of current analytical approaches,
suggest limits to the value of such data.100 The quality of real world
95. Id. § 356(g)(6)(B)(ii).
96. See Zachary Brennan, Real World Evidence: FDA Commits to Advancing Its Use, RAPS (Sept.
19, 2017), http://www.raps.org/Regulatory-Focus/News/2017/09/19/28491/Real-World-Evidence-FDACommits-to-Advancing-its-Use/ [https://perma.cc/K7FX-9KB9] (describing FDA Commissioner Scott
Gottlieb’s remarks to the National Academy of Sciences’ workshop on incentivizing providers to enter
data into electronic medical records at the point of care).
97. 21 U.S.C. § 356(g)(7)(A–C).
98. Id. § 356(c)(2)(A).
99. Rachel E. Sherman et al., Real-World Evidence—What Is It and What Can It Tell Us, 357 NEW
ENG. J. MED. 2293, 2293, 2295 (2016) (referencing the Salk field trial of the polio vaccine).
100. Id.
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evidence may be less robust than that collected in randomized
clinical trials because real world evidence is not subject to the same
rigorous quality requirements, like the use of eligibility criteria,
detailed case reporting forms, and intensive monitoring.101 Rather, its
collection is often not for the purpose of supporting research, and is
likely not optimized or organized for research purposes.102
Stakeholders are developing methods to incorporate real world
evidence into research, and efforts are ongoing.103 Current
limitations, however, are particularly evident when real world
evidence is intended to support the effectiveness of a product and the
expected or observed effect is relatively small.104
The RMAT approval pathway is only available to those products
that meet the eligibility requirements by intending to treat serious or
life-threatening diseases or conditions and filling an unmet medical
need.105 This reflects a policy judgment that patients with serious or
life-threatening diseases without access to treatment should be
permitted to trade certainty for earlier access.
II. Defenses and Critiques of Existing Regulation
Critics charge the FDA with over-regulating regenerative medicine
therapies.106 They point to patients with serious illnesses for whom a
delay in product approval may prove fatal.107 At the extreme, some
stakeholders argue that regenerative medicine therapies, or at least
significant subsets, should not be regulated at all. For example, in
U.S. v. Regenerative Sciences, the defendant unsuccessfully argued to
the District of Columbia Circuit Court that the regenerative medicine
product at issue was not a drug, biological product, or tissue product,
but rather the practice of medicine.108 Because this case and its
101. Id. at 2293.
102. Sherman et al., supra note 99, at 2294.
103. Id.
104. Id. at 2295.
105. 21 U.S.C. § 356(g)(2)(B)–(C).
106. See, e.g., Riley, supra note 17, at 465; c.f., Margaret Hamburg, M.D. & Joshua M. Sharfstein,
M.D., The FDA as a Public Health Agency, 360 NEW ENG. J. MED. 2493, 2493 (2009).
107. See Hamburg & Sharfstien, supra note 106, at 2493.
108. United States v. Regenerative Sciences, LLC, 741 F.3d 1314, 1319 (D.C. Cir. 2014).
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implications have been thoroughly analyzed elsewhere,109 I will not
restate the issues, but the court was right to deny the defendant’s
argument, for both legal and normative reasons. Fundamentally,
regulation of regenerative medicine therapies is important to protect
the public health and to encourage data generation that advances
scientific understanding of the field.
A. Why Regulation is Important
The goal of public health is to “fulfill . . . society’s interests in
assuring the conditions in which people can be healthy.”110 As a
public health agency, the FDA supports the goal of assuring healthy
conditions not only by ensuring the safety, efficacy, and security of
medical products like drugs, devices, and biologics, but also by
“helping to speed innovations that make medical products more
effective, safer, and more affordable and by helping the public get the
accurate, science-based information they need to use medical
products.”111
To ensure the safety, efficacy, and security of new products, the
FDA seeks to reduce harms before they occur by acting as a
gatekeeper to the marketplace for new biologics and drugs.112 To do
this, the FDA evaluates evidence of a product’s safety and efficacy
submitted by the product sponsor, and balances the potential benefits
that a therapy can provide with its potential harms.113 When
109. See, e.g., Mary Ann Chirba & Stephanie Garfield, FDA Oversight of Autologous Stem Cell
Therapies: Legitimate Regulation of Drugs and Devices or Groundless Intervention with the Practice of
Medicine?, 7 J. HEALTH & BIOMEDICAL L. 233, 253, 271 (2011); Greg Pivarnik, Cells as Drugs?
Regulating the Future of Medicine, 40 AM. J. L. & MED. 298, 319 (2014); Barbara von Tigerstrom, The
Food and Drug Administration, Regenerative Sciences, and the Regulation of Autologous Stem Cell
Therapies, 66 FOOD & DRUG L.J. 479, 504 (2011).
110. Hamburg & Sharfstein, supra note 106, at 2493 (providing the Institute of Health’s definition of
“public health”).
111. U.S. FOOD & DRUG ADMIN., What We Do, https://www.fda.gov/aboutfda/whatwedo/
[https://perma.cc/5C7J-5PGK] (last updated Dec. 29, 2017).
112. See Sidney Shapiro & Robert L. Glicksman, RISK REGULATION AT RISK: RESTORING A
PRAGMATIC APPROACH 6 (2003) (quoting John Applegate, The Perils of Unreasonable Risk:
Information, Regulatory Policy, and Toxic Substances Control, 91 COLUM. L. REV. 261, 273 (1991))
(“Regulation based on risk permits regulatory action based on ex ante collective danger rather than ex
post individual injury, and also operates preventively to avert injury to the public as a whole.”).
113. Hamburg & Sharfstein, supra note 106, at 2492.
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determining whether to approve a product, the agency considers the
severity of the targeted disease or condition, whether alternative
treatments are available, and the level of knowledge about patient
responses to the therapy.114
This gatekeeping function is vital for patient protection because a
patient, by herself, has inadequate information to determine whether
a drug or biologic is safe and effective even after receiving it.115
Although the patient can certainly identify whether she feels better or
worse after receiving a drug or biologic intervention, factors other
than the therapy may cause some or all of the change in her
wellbeing.116 Because of this inability to judge the therapy even after
experiencing it, the patient must rely on the expertise of her doctor
both to determine her need for treatment and to choose the correct
medical treatment.117 A dishonest doctor could exploit the patient’s
lack of information by recommending a product or treatment that is
unnecessary, ineffective, harmful, or more expensive than other
options.118 Regulations that reduce this information asymmetry by
demanding that products demonstrate safety and effectiveness before
entering the marketplace help protect patients against receiving
unsafe or ineffective treatments.
The FDA’s role in public health is not limited to approving or
denying applications for premarket approval. It has another mission,
114. Id.
115. STEPHEN BREYER, REGULATION AND ITS REFORM 28 (1982); W. Nicholson Price II, Regulating
Black-Box Medicine, 116 MICH. L. REV. 421, 461–65 (2017); Michael R. Darby & Edi Karni, Free
Competition and the Optimal Amount of Fraud, 16 J. L. & ECON. 67, 81 (1973) (introducing the concept
of credence goods).
116. This is, of course, the reason that randomized, controlled trials remain the gold-standard in
determining the safety and efficacy of new treatments. See, e.g., Bonnie Sibbald & Martin Roland,
Understanding Controlled Trials: Why Are Randomised Trials Important?, 316 BRIT. MED. J. 201, 201
(1998).
117. See, e.g., Uwe Dulleck & Rudolf Kerschbamer, On Doctors, Mechanics, and Computer
Specialists: The Economics of Credence Goods, 44 J. ECON. LIT. 5, 6 (2006).
118. Dulleck and Kerschbamer provide specific examples that demonstrate that information
asymmetry matters in medical decision-making. A 1997 Swiss study reported that the average person’s
likelihood of receiving one of seven major surgeries was one-third greater than that of a physician or a
physician’s family member. See id. at 6 (citing Winand Emons, Credence Goods and Fraudulent
Experts, 28 RAND J. ECON. 107 (1997)). A Federal Trade Commission study revealed the tendency of
optometrists to prescribe unnecessary treatments. See id. at 6 (citing Asher Wolinsky, Competition in a
Market for Informed Experts’ Services, 24 RAND J. ECON. 380 (1993)).
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to promote innovation that makes drugs and biologics safer, more
effective, and more affordable.119 And it uses its gatekeeper
requirements for this purpose as well. By requiring private firms to
submit clinical trial evidence for premarket approval, the FDA
incentivizes those firms to create valuable data on the risks and
benefits of medical products.120 This information is used not only to
advise doctors and patients,121 but also to further scientific
understanding of how the medical product acts within the human
body.122 This understanding enhances biomedical knowledge, and
researchers and firms can use it to increase the efficiency of research
and development of new potential therapies.123
Regenerative medicine therapies are appropriate subjects for premarket regulation both to protect patients and to promote innovation.
Harms from unsafe or ineffective regenerative medicine treatments
can manifest as economic, physical, or opportunity cost harms.
Additionally, data from clinical trials can advance the state of
understanding of how regenerative medicines affect the human body.
1. Economic Harms
Economic harm occurs when a patient spends money on a therapy
that does not provide the benefits promised by its marketing or
advertising claims.124 This was the underlying claim in a putative
class action lawsuit against Stemgenex Medical Group, Inc., a stem
cell clinic in southern California.125 The five named plaintiffs
119. Eisenberg, supra note 76, at 370.
120. Id.
121. See, e.g., Wash. Legal Found. v. Friedman, 13 F. Supp. 2d 51, 69 (D.D.C. 1998) (dismissed on
appeal as moot) (upholding substantial government interest in ensuring that physicians receive accurate
and unbiased information so that they make informed prescription choices); Eisenberg, supra note 76, at
374 (“The doctors who prescribe drugs are the principle targets of information dissemination by
pharmaceutical firms, although in recent years pharmaceutical firms have increasingly advertised their
products directly to patients.”).
122. Daria Kim, Knowledge Sharing as a Social Dilemma in Pharmaceutical Innovation, 71 FOOD &
DRUG L.J. 673, 691–92 (2016).
123. Id.
124. See, e.g., Dulleck & Kerschbamer, supra note 117, at 6.
125. Fourth Amended Complaint at 2, Moorer v. Stemgenex Med. Grp., Inc., No. 3:16-cv-02816AJB-NLS, 2017 WL 3992747(S.D. Cal. May 18, 2017); see also Michael Hiltzik, The Stem Cell
Therapies Offered by this La Jolla Clinic Aren’t FDA Approved, May Not Work—and Cost $15,000,
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suffered from various conditions, including lupus, diabetes, a
“painful condition affecting [plaintiff’s] spine and joints,” and
multiple sclerosis.126 They alleged that, because of the stem cell
clinic’s marketing claims, they spent $14,900 per treatment on stem
cell therapy that had no beneficial effect.127 Similarly, a separate
lawsuit against the Lung Institute, a Florida-based stem cell clinic,
alleged that the clinic promised that its stem cell therapies would
treat lung disease, charged the plaintiff $7,500 for the initial
treatment, and then blamed her for the treatment’s ineffectiveness
because she could not afford monthly “reboost” shots costing an
additional $70 per month.128 Instead of benefiting the patients’
wellbeing, these expensive treatments caused them economic harms.
2. Physical Harms
Even more troubling are the direct physical harms that patients
may suffer from regenerative medicine therapies. Physical harms
have occurred in both clinical trial settings and in unregulated stem
cell clinics. Harms in some regenerative medicine trials have been
well-publicized. For example, two patients’ deaths in a 2016 gene
editing cancer treatment trial caused the FDA to halt the trial.129
Unregulated treatments from stem cells clinics have also caused
significant physical harms. Two separate lawsuits filed by patients
against a Florida stem cell clinic alleged that the clinic directly
injected a purported stem cell therapy into their eyes as treatment for
macular degeneration.130 As a result, the plaintiffs alleged that they
L.A. TIMES (Mar. 31, 2017, 1:50 PM), http://www.latimes.com/business/hiltzik/la-fi-hiltzik-stemgenex20170330-story.html [https://perma.cc/G2SU-2AB7].
126. Fourth Amended Complaint, supra note 125, at 3–5.
127. Id. at 5. The Fourth Amended Complaint incorporates screen shots from StemGenex’s website
that touts “stem cell therapy studies” for autoimmune diseases, diabetes, multiple sclerosis, and
osteoarthritis and rheumatoid arthritis, among other conditions. Id. at 11–14.
128. Complaint at 4, Rivero v. Lung Institute, LLC, No. 45360019 (Fla. Cir. Ct. Aug. 14, 2016); see
also Tony Marrero, Unsatisfied Former Patient Files Class-Action Lawsuit Against Lung Institute,
TAMPA BAY TIMES (Aug. 26, 2016, 1:27 AM), http://www.tampabay.com/news/courts/civil/unsatisfiedformer-patient-files-class-action-lawsuit-against-lung/2290989 [https://perma.cc/H3FM-R76S].
129. Damian Garde & Meghana Keshavan, Two Patient Deaths Halt Trial of Juno’s New Approach to
Treating Cancer, STAT (Nov. 23, 2016), https://www.statnews.com/2016/11/23/juno-cancerimmunotherapy-deaths-2/ [https://perma.cc/Y4LM-8RDW].
130. Amended Complaint for Damages and Demand for Jury Trial at 1, Bade v. Greenbaum, No.:

https://readingroom.law.gsu.edu/gsulr/vol34/iss3/3

22

Duranske: Reforming Regenerative Medicine Regulation

2018]

REFORMING REGENERATIVE MEDICINE REGULATION

653

suffered permanent damage, including blindness.131 Another patient,
a sixty-six-year-old man who sought treatment for lingering effects
from an ischemic stroke, received multiple stem cell injections,
described as mesenchymal, embryonic, and fetal neural, at several
clinics outside the United States.132 He developed a massive lesion
growing around his spinal cord; a biopsy revealed that the cells were
not from his body. He developed lower back pain, paraplegia, and
urinary incontinence.133 In another example, a boy who received fetal
stem cell transplants at age nine developed abnormal growths in his
brain and spinal cord.134 Researchers discovered that the brain tumor
contained cells from two or more donors, at least one of whom was
female, suggesting that the stem cells caused the tumor.135
3. Opportunity Cost Harms
Patients who receive regenerative medicine therapies may forego
conventional treatment options that are more effective, less harmful,
or less expensive. By choosing an inferior regenerative medicine
therapy instead of a different, superior therapy, a patient suffers not
only economic or physical harms wrought by the therapy, but also the
lost value that she would have received from the superior therapy. It
is hard to quantify this risk. In one sense, because many developing
regenerative medicine therapies are intended to treat or mitigate the
effects of diseases or conditions that have no current effective
2015-021463 CA 30 (Fla. Cir. Ct. July 19, 2016) [hereinafter Bade Complaint]; Complaint at 2, Noble
v. U.S. Stem Cell, Inc., No: CACE-15-021101 (04) (Fla. Cir. Ct. Nov. 30, 2015) [hereinafter Noble
Complaint].
131. The Bade complaint specifically alleges that the plaintiffs suffered permanent blindness. Bade
Complaint, supra note 130, at 1. The Noble complaint did not specifically allege this fact; both
complaints listed identical damages. See id. at 11; Noble Complaint, supra note 130, at 16 (noting that
alleged damages include “bodily injury; pain and suffering; disability; disfigurement; loss of the
capacity for the enjoyment of life; aggravation of pre-existing conditions; medical and hospital care and
expenses; loss of earnings; loss of earning capacity in the future; rehabilitation expenses; and mental
distress”).
132. U.S. FOOD & DRUG ADMIN., DRAFT GUIDANCES RELATING TO THE REGULATION OF HUMAN
CELLS, TISSUES, OR CELLULAR OR TISSUE-BASED PRODUCTS 106 (Sept. 12, 2016).
133. Id.
134. Ninette Amariglio et al., Donor-Derived Brain Tumor Following Neural Stem Cell
Transplantation in an Ataxia Telangiectasia Patient, 6 PLOS MEDICINE 221, 223 (2009).
135. Id. at 255–26.
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treatment, the potential for opportunity cost harms may be relatively
small. But past experience demonstrates that opportunity cost harms
are not merely theoretical, and will likely increase as additional
regenerative medicine therapies become available.136
History provides us with a compelling example of opportunity
cost. Between 1985 and 1998, over 30,000 women in the United
States with breast cancer received high-dose chemotherapy plus
autologous bone marrow transplants instead of the standard-dose
treatments for breast cancer.137 Early observations of tumor shrinkage
in the 1980s, followed by Phase 2 clinical trials reporting improved
survival rates, excited researchers and patients.138 Although the
treatment was expensive at $80,000,139 and “very toxic,”140 the
combined forces of patients’ hopes, powerful lobbying efforts,
oncology researchers, and media coverage drove the adoption of this
novel therapy.141 But more critical inquiries in the early 1990s noted
methodological shortcomings in the Phase 2 trials, particularly
selection bias.142 As additional Phase 2 and Phase 3 trial results were
published in the late 1990s that indicated high-dose chemotherapy
plus autologous bone marrow transplants did not increase the
patients’ survival rates, enthusiasm for the treatment plummeted.143
But those patients who received the treatment forewent the
opportunity to receive conventional breast cancer treatment that
involved decidedly fewer side effects. Instead, these patients’ choice
of the novel treatment exposed them to risks of acute-onset toxicities,
136. See Michelle M. Mello & Troyen A. Brennan, The Controversy Over High-Dose Chemotherapy
with Autologous Bone Marrow Transplant for Breast Cancer, 20 HEALTH AFFAIRS 101, 101 (2001).
137. Daniel F. Hayes, False Hope: Bone Marrow Transplantation for Breast Cancer, 357 N. ENGL. J.
MED. 1059, 1059 (2007) (book review); see also Mello & Brennan, supra note 136, at 110 (estimating
that 42,680 autologous bone marrow transfers were performed on breast cancer patients between 1990
and 1999).
138. Mello & Brennan, supra note 136, at 103.
139. Id. at 102.
140. Id. (quoting Position Statement, Am. Soc’y of Clinical Oncology, High-Dose Chemotherapy
with Bone Marrow Transplant for Breast Cancer Patients, (Mar. 2000) (on file with author)).
141. Id. at 106–07.
142. Id. at 103.
143. Id. For one significant study demonstrating no benefit, see S. Rodenhuis et al., Randomised Trial
of High-Dose Chemotherapy and Haemopoietic Progenitor-Cell Support in Operable Breast Cancer
with Extensive Axillary Lymph-Node Involvement, 352 LANCET 515 (1998).
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such as sepsis and pulmonary failure, and, among others, leukemia,
bone marrow insufficiency, psychosexual disorders, increased
vulnerability to infection, and even death.144
4. Furthering Scientific Understanding
Requiring clinical trials to demonstrate safety and efficacy can also
further the field of regenerative medicine. Cells are extraordinarily
complex, which makes predicting their behavior in a new
environment challenging.145 Clinical trial data can further the science
of regenerative medicine. Publication of clinical trial results can
“promote transparency in the clinical translation of stem cell-based
therapies, . . . ensure development of clinically effective and
competitive stem cell-based therapies, . . . prevent individuals in
future clinical trials from being subjected to unnecessary risk,
and . . . respect research subjects’ contribution.”146 As former FDA
officials cautioned, “[W]e must first understand [a regenerative
medicine therapy’s] risks and benefits and develop therapeutic
approaches based on sound science. Without a commitment to the
principles of adequate evidence generation that have led to so much
medical progress, we may never see stem-cell therapy reach its full
potential.”147
B. Stakeholder Critiques
At a public hearing in September 2016, the FDA solicited
feedback from stakeholders on the regulation of regenerative
medicine therapies.148 Participants raised many specific issues, but
two arose time and again: the regulation of allografts (tissue
144. Mello & Brennan, supra 136, at 110–11.
145. Peter W. Marks, Celia M. Witten & Robert M. Califf, Clarifying Stem-Cell Therapy’s Benefits
and Risks, 376 NEW ENG. J. MED. 1007, 1008 (2017).
146. INT’L SOC’Y FOR STEM CELL RESEARCH, GUIDELINES FOR STEM CELL RESEARCH AND CLINICAL
TRANSLATION 24 (2016).
147. Marks et al., supra note 145, at 1007.
148. See, e.g., Riley, supra note 17, at 458; c.f., Hamburg & Sharfstein, supra note 106, at 2493
(stating that “the ultimate measures of the FDA’s success should reflect its fundamental goals and go
beyond such intermediate measures as the number of facilities inspected or drugs approved”).
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transplants from one person to another) and the regulation of
unapproved stem cell therapies.149 On both issues, some stakeholders
argued for less robust regulation while others defended the existing
structure and argued for stronger enforcement of the existing
regulations.150
Regulatory economist Bruce Yandle observed that interest groups
are more powerful when two factions join together: the
economically-motivated, and those providing a moral justification for
the same regulatory policy.151 His colorful name for this theory,
“Bootleggers and Baptists,” derives from two distinct groups’
support for a law that required liquor stores to close on Sundays. The
Baptists supported the law for religious purposes, while the
bootleggers supported the law because the absence of competition
once a week increased demand for their product. The coalition of
Baptists and bootleggers made it easier for politicians to favor both
groups–they could present themselves as being motivated by the
public interest, while benefitting from the financial support of the
bootleggers.152 Scholars have observed the persuasive power of
similar alliances across a number of regulatory settings.153 The
coalition of stakeholder interests in regenerative medicine provides
another such example.
First, consider allografts. Some stakeholders advocated for a looser
interpretation of the section 361 requirements so that their products
would qualify as section 361 products and fall under the intermediate
regulatory tier instead of the more stringent biologics tier.154 But in
149. U.S. FOOD & DRUG ADMIN., CTR. FOR BIOLOGICS EVALUATION AND RESEARCH, PART 15
HEARING: DRAFT GUIDANCES RELATING TO THE REGULATION OF HUMAN CELLS, TISSUES, OR
CELLULAR OR TISSUE-BASED PRODUCTS 29 (Sept. 12, 2016) [hereinafter CBER HCT/Ps Hearing, Sept.
12, 2016].
150. Id.
151. ADAM SMITH & BRUCE YANDLE, BOOTLEGGERS & BAPTISTS: HOW ECONOMIC FORCES AND
MORAL PERSUASION INTERACT TO SHAPE REGULATORY POLITICS at viii (2014).
152. Id.
153. Id.; see also Jonathan H. Adler et al., Baptists, Bootleggers & Electronic Cigarettes, 33 YALE J.
ON REG. 313 (2016).
154. See, e.g., CBER HCT/Ps Hearing, Sept. 12, 2016, supra note 149, at 20–21 (statement of Pamela
Vetter, director of regulatory policy at Allosource, a nonprofit cellular and tissue network, arguing for
broader definitions of “original relevant characteristics” and “main function”); id. at 71 (statement of Dr.
Justin Deurling, RTI Surgical, a manufacturer and distributor of HCT/Ps, arguing for a broader reading
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response, an alliance of financial and moral interests defended the
existing requirements for premarket approval. Representing financial
interests were those firms that manufacture products subject to the
highest tier of FDA regulation. For example, at the hearing, the
company that makes Apligraf, an FDA-approved product, argued that
competitive products should be required to obtain premarket
approval.155 Representing the moral interest were healthcare
providers who warned the FDA that patients’ health may be put at
risk when allograft products are marketed without FDA approval
because healthcare providers may unknowingly use an allograft that
has not undergone the clinical trials required for FDA approval.156
Dr. Scott James, a vascular surgeon at Beth Israel Deaconess
Plymouth Hospital explained, “The patients that we see in our
practice have devastating conditions and the consequences of using
treatments that are not backed by rigorous science can be disastrous.
Our patients deserve to know that the therapies we give them have
been proven to be both safe and effective.”157
Similar alliances arose around unapproved stem cell treatments
with Baptists and bootleggers on both sides. Stakeholders who claim
that the FDA overregulates stem cells point to the FDA’s approval of
a single class of stem cell products as evidence that the FDA moves
too slowly.158 Industry representatives, who would benefit financially
from lighter regulation, argued that autologous stem cell therapies
should not be regulated, and raised concerns of federalism and
patient autonomy.159 Patients and their advocates lent moral credence
of “minimal manipulation” to cover certain sterilization and decellularization techniques).
155. Id. at 67.
156. See, e.g., U.S. FOOD & DRUG ADMIN. CTR. FOR BIOLOGICS EVALUATION AND RESEARCH, PART
15 HEARING: DRAFT GUIDANCES RELATING TO THE REGULATION OF HUMAN CELLS, TISSUES, OR
CELLULAR OR TISSUE-BASED PRODUCTS 96 (Sept. 13, 2016) [hereinafter CBER HCT/Ps Hearing, Sept.
13, 2016] (statement of Dr. Harold Brem, Surgeon and Professor of Surgery at Stony Brook University
School of Medicine); id. at 132 (statement of Marie Louise Gehling, N.P.); id. at 181 (statement of
Sheila Sabon DeCastro, N.P. at Mass General Hospital and a consulting director to the tissue program at
Beth Israel Deaconness Hospital Plymouth).
157. Id. at 149.
158. Alexey Bersnenev, Is FDA Slowing Down the Progress in Clinical Cell Therapy?, STEM CELL
ASSAYS (Nov. 27, 2011), http://stemcellassays.com/2011/11/fda-slowing-progress-cell-therapy/
[https://perma.cc/8RFV-X774].
159. See, e.g., CBER HCT/Ps Hearing, Sept. 12, 2016, supra note 149, at 81–82 (statement of Kristin
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to these claims. One patient suffering from rheumatoid arthritis
obtained an unapproved adipose-derived treatment from a stem cell
clinic in California and credited the treatment with her remission.160
Another patient suffering from juvenile idiopathic arthritis credited
an unapproved adipose–derived treatment with drastically improving
her quality of life.161 Still another credited a similar treatment with
alleviating her multiple sclerosis symptoms.162
But other stakeholders argued for increased enforcement of
existing regulations, and included health care providers and
representatives of competing products regulated as biologics.163 Not
only do unapproved stem cell treatments lack scientific evidence of
efficacy,164 they argued, but patients also have insufficient
information to understand the treatments165 and may suffer physical
harm.166
Comella, U.S. Stem Cell); id. at 151 (statement of Dr. Elliott Lander, Cell Surgical Network); id. at 153
(statement of Michael Badowski, AdiCyte). A significant point, oft repeated, was the claim that the
treatments offered by stem cells clinics are like surgery, and thus should be included in the same
surgical procedure exception. Id. The second major argument was that of patient autonomy: “Patients
have a right to provide informed consent decision about how they’re going to use these treatments
themselves. They have a right to alternative therapies.” Id. at 85. Another similar argument was raised:
“Why would the FDA regulate our own body tissue and consider this a drug?” Id. at 83.
160. See CBER HCT/Ps Hearing, Sept. 13, 2016, supra note 156, at 109–10 (statement of Georgianna
Crocker).
161. See id. at 142–43 (statement of Sarah Hughes).
162. See id. at 168–70 (statement of Kristin Marr).
163. See, e.g., CBER HCT/Ps Hearing, Sept. 12, 2016, supra note 149, at 44–45 (statement of Dr.
Eric Daniels). Even these competing manufacturers couched their advocacy in publicly-interested
terminology. Consider the statements of Dr. Eric Daniels, the chief medical officer of Kerastem
Technologies, which sponsors a Phase 2 trial investigating the role of adipose and its derivative stromal
vascular fraction for genetic alopecia. Dr. Daniels warned that after a decade and a half of cell therapies,
“we still lack certainty around critical issues of identity, purity, and dose response.” Id. at 44–45. He
continued, “Ad hoc manufacturing in an operating room, using unregulated systems and tools and/or
processes, as well as negligent promotion will not help uncover and, more importantly, broadly
disseminate the therapeutic potential—in this case of adipose-derived therapies. This will only come
from a series of focused, well-designed, and controlled clinical trials.” Id.
164. See CBER HCT/Ps Hearing, Sept. 13, 2016, supra note 156, at 156 (Jeanne Loring, stem cell
researcher at the Scripps Research Institute, stated, “Adipose cell therapy is governed by that overused
axiom, if the only tool you have is a hammer, you will treat everything as if it is a nail. It isn’t logical or
scientific to assume that all disorders can be treated with a single type of cell.”)
165. See CBER HCT/Ps Hearing, Sept. 12, 2016, supra note 149, at 97 (statement of Dr. Steve Bauer,
FDA, reviewing September 8,, 2016, workshop of Scientific Evidence in development of HCT/P
products that are subject to premarket approval). On the concern that stem cell clinics may untruthfully
or confusingly allege that the therapies are part of a clinical trial subject to IRB approval, see Paul
Knoepfler, Does Stem Cell Clinic IRB Approval Mean Much? Insights from Blinding Cases, NICHE
(Mar. 23, 2017), https://ipscell.com/2017/03/does-stem-cell-clinic-irb-approval-mean-much-insights-
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The Bootleggers and Baptists theory suggests the use of financial
incentives to sway a policymaker’s support. And although it is nearly
impossible to link financial contributions directly to policymaker
action, it is worth noting that the regenerative medicine arena is
subject to the same lobbying influences as many other areas. For
example, MiMedx, a for-profit company that sells regenerative
products created from amniotic tissue, received an untitled letter from
the FDA in 2013 asserting that the company’s product failed to
receive the proper premarket approval. In 2016, MiMedx contributed
ten thousand dollars to the campaign of the senator who introduced
the REGROW Act, the reform bill discussed in the next section.167
III. Reform of Section 351 Products
Building on the criticism that the FDA’s regulation of regenerative
medicine products is overinclusive and too slow, reform advocates
have pushed for speedier FDA review in the form of adaptive
licensing. Under this proposed framework the FDA would approve a
product based on less-than-standard clinical evidence of efficacy and
safety, and would restrict patient access to the product while the
sponsor gathers postmarket evidence of the product’s effect in a real
world setting. Then, based on the evidence continuously gathered, the
FDA could withdraw the product’s initial approval, adjust marketing
restrictions, or lift the restrictions altogether. 168
While adaptive licensing offers the benefits of early market access
and the continued generation of evidence of a product’s safety and
effectiveness (or purity and potency), a closer analysis reveals
from-blinding-case/ [https://perma.cc/7SPV-XBUG].
166. CBER HCT/Ps Hearing, Sept. 12, 2016, supra note 149, at 105–06.
167. Paul Knoepfler, REGROW Act, Mark Kirk Lobbying & Contributions Yield Stem Cell Surprises,
NICHE (Nov. 3, 2016), https://ipscell.com/2016/11/regrow-act-mark-kirk-lobbying-contributions-yieldstem-cell-surprises/ [https://perma.cc/6VNL-JLHC]; Candidate Information for Mark Kirk, FED.
ELECTION COMM’N, https://classic.fec.gov/finance/disclosure/candcmte_info.shtml
[https://perma.cc/RH3V-DKEM] (last visited Mar. 5, 2018) (searching “Mark Kirk” in the “partial
name” field). Astellas Pharma, a Japanese pharma company involved in stem cell research, also made a
contribution to Kirk’s campaign. Id.
168. Shannon Gibson & Trudo Lemmens, Niche Markets and Evidence Assessment in Transition: A
Critical Review of Proposed Drug Reforms, 22 MED. L. REV. 200, 208 (2014). This is called “adaptive
licensing.” Id.
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fundamental flaws. Not only would it require Congress to grant new
authority to the FDA, but the risk of harm to patients and practical
barriers to industry participation make such a framework unworkable
and unwise. A structural overhaul of the premarket approval system
would be expensive, and evidence suggests that regulatory science is
not yet able to accurately predict when the potential benefits of early
access outweigh the risks of harm.
This section outlines three proposals for adaptive licensing. By
evaluating the proposals using a theory of adaptive regulation, I
conclude that implementing an adaptive licensing scheme does not
offer sufficient benefits to outweigh the risks and burdens.
A. Adaptive Licensing
Adaptive licensing reform proposals reached a zenith in the
REGROW Act, which was introduced in 2015 but ultimately died
without a vote.169 It did, however, set the stage for the inclusion of
RMAT provisions in the 21st Century Cures Act, which passed the
following year.170 The REGROW Act arose from the proposals that
preceded it: Arnold Caplan co-authored the initial proposal, then
served as an “expert panelist” with the Bipartisan Policy Center
during its promulgation of the second proposal.171 Mark Kirk, the
politician who introduced the third proposal, the REGROW Act,
specifically credited the Bipartisan Policy Center report when he
introduced his bill. 172

169. See S. 2689 – REGROW Act, CONGRESS.GOV, https://www.congress.gov/bill/114thcongress/senate-bill/2689 [https://perma.cc/FV4G-4QAE] (last visited Jan. 14, 2018).
170. 21st Century Cures Act, sec. 3033, 130 Stat. 1101 (2016) (codified at 21 U.S.C. § 356).
171. Michael Eisenstein, Regulation: Rewriting the Regenerative Rulebook, 540 NATURE S65, S66
(2016) (“Caplan helped formulate the REGROW Act.”), https://www.nature.com/articles/540S63a.pdf
[https://perma.cc/KAD4-SR3T].
172. Press Release, Office of Senator Mark Kirk, REGROW Act Accelerates New Therapies to Help
Patients Living with Disease; Stem Cell Therapies Help Alzheimer’s, Parkinson’s, Sickle Cell Patients
(Mar. 16, 2016) (on file with author); see also Cade Hildreth, Kirk, Manchin, Collins Introduce Bill to
Speed Development of Regenerative Medicine, BIOINFORMANT (Mar. 16, 2016),
https://www.bioinformant.com/kirk-manchin-collins-introduce-bill-to-speed-development-ofregenerative-medicine/#more-5609 [http://perma.cc/GVY5-4JRZ].
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1. Describing Adaptive Licensing
Adaptive licensing exemplifies a lifecycle approach to medical
product evaluation where market access for drugs is progressive.173
The model diverges from the traditional approval model where a drug
transitions from experimental to approved in a single moment, and
grows from the principle that there is no “magic moment” when
regulators can conclusively determine that a drug is safe and
effective.174 Adaptive licensing frameworks envision two (or more)
stages in a licensing pathway.175 In the first stage, a drug receives an
initial license based on less rigorous evidence than the two Phase 3
randomized controlled trials typically required for approval.176 The
initial patient population is restricted; the particular restrictions
depend on the product’s particular issues and the level of knowledge
about the product’s use.177 In the second stage, after the initial license
is granted, the sponsor continues to generate evidence on the drug’s
use.178 This evidence could “encompass the full methodology
spectrum, including randomly-controlled clinical trials (RCTs),
pragmatic clinical trials, clustered RCTs, observational studies based
on electronic medical records, registries, and other forms of active
and passive surveillance.”179 Access expands, or the drug is
withdrawn, as the sponsor reports additional postmarket evidence of
safety and effectiveness.180

173. See, e.g., Gibson & Lemmens, supra note 168, at 208; W. Nicholson Price II & Arti K. Rai,
Manufacturing Barriers to Biologics Competition and Innovation, 101 IOWA L. REV. 1023, 1061
(2016); Anna B. Laakmann, Collapsing the Distinction Between Experimentation and Treatment in the
Regulation of New Drugs, 62 ALA. L. REV. 305, 332 (2011) (discussing adaptive licensing for new
drugs). W. Nicholson Price II, supra note 115, at 461–65 (discussing adaptive licensing for medical
algorithms).
174. Eichler, supra note 77, at 427; see also Laakmann, supra note 173, at 308.
175. Eichler, supra note 77, at 430.
176. INST. OF MED. (US) COMM. OF ACCELERATING RARE DISEASE RESEARCH & ORPHAN PROD.
DEV., RARE DISEASES AND ORPHAN PRODUCTS: ACCELERATING RESEARCH AND DEVELOPMENT 155
(Marilyn J. Field & Thomas F. Boat eds., 2010).
177. Arnold I. Caplan & Michael D. West, Progressive Approval: A Proposal for a New Regulatory
Pathway for Regenerative Medicine, 3 STEM CELLS TRANSLATIONAL MED. 560, 562 (2014); Eichler,
supra note 77, at 430.
178. Caplan & West, supra note 177, at 561.
179. Eichler, supra note 77, at 429.
180. Id. at 431; Caplan & West, supra note 177, at 561.
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Depending on the risk factors of the product, the path to approval
would vary for each therapy.181 Just as the current system’s
accelerated approval pathway acknowledges that patients,
practitioners, and regulators are willing to trade greater unknowns
about safety and effectiveness to enable access for patients facing
life-threatening or serious conditions with a lack of treatment options,
an adaptive licensing framework would expect that other trade-offs
between certainty and access might be acceptable in scenarios less
extreme than those that already qualify for accelerated approval.182
Three proposals suggest variations on the theme of adaptive
licensing for regenerative medicines, but differ in important aspects.
First, they differ as to which therapies qualify. Under the Caplan and
West proposal, only those therapies that offer an advantage in
treating serious diseases are eligible for adaptive licensing, whereas
the other two restrict eligibility to certain lower-risk therapies.
Second, they differ as to the evidence required for approval. The
Caplan and West proposal demands only pretrial and Phase 1 studies,
while the other two require both Phase 1 and Phase 2 trials. Third,
they vary on postmarketing controls. The Caplan and West proposal
suggests the use of significant controls to slow product diffusion into
the marketplace, while the other two suggest no controls to slow
diffusion, but do implement monitoring and reporting requirements
(Bipartisan Policy Center) or informed consent requirements
(REGROW Act). As I will address in the following subsection,
weaknesses in each of these proposals renders them impracticable
and unwise.
2. Caplan and West
In a 2014 article in a scientific journal, Caplan and West proposed
an alternate regulatory pathway that would allow the marketing of
regenerative medicine therapies without any evidence of efficacy.183
Under their proposal, a therapy would be subject to two regulatory
181. Eichler, supra note 77, at 428.
182. See id. at 427.
183. Caplan & West, supra note 177, at 561.
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steps. The first step would establish product safety through
preclinical assessments of the therapy’s proposed mechanism of
action and Phase 1 clinical trials.184 Based on this preliminary
evidence, the therapy would be approved for marketing.185 In the
second step, postmarketing studies would rely on inputs from
physicians and patients to “capture, in real time, the full experience
of a large population.”186 Effectiveness would be established through
this postmarket evidence-gathering.187 The sponsor would also be
required to conduct a five-to-ten year follow up to establish the longterm safety of the procedures.188 Only those therapies intended to
provide a meaningful advancement in the treatment of a serious or
life-threatening disease would be eligible.189 The product’s diffusion
through the marketplace would be controlled through distribution
restrictions, physician training, and credentialing.190 Under Caplan
and West’s proposal, the therapies on the market would not be
considered “investigational,” so they would be subject to the same
coverage and reimbursement policies as therapies that are approved
after demonstrating efficacy.191
3. The Bipartisan Policy Center Report
The Bipartisan Policy Center issued a report in December 2015
entitled, “Advancing Regenerative Cellular Therapies.”192 The report
called for the creation of a new regulatory pathway for regenerative
medicine therapies regulated as biologics.193 To qualify, a product
would have to meet a set of criteria designed to exclude the highest
risk therapies.194 Therapies that fall under this new pathway would be
184. Id.
185. Id.
186. Id.
187. Id.
188. Id.
189. Caplan & West, supra note 177, at 561.
190. Id. at 562.
191. Id. at 562.
192. BIPARTISAN POLICY CTR., ADVANCING REGENERATIVE MEDICINE: MEDICAL INNOVATION FOR
HEALTHIER AMERICANS 1 (2015).
193. Id. at 12.
194. Id. at 13–15. The qualifying products either would be (1) (A) intended for homologous use and
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conditionally approved based on Phase 1 and Phase 2 trials
demonstrating safety and efficacy.195 Patients would have access to
these conditionally-approved therapies subject to monitoring and
reporting requirements to the FDA.196 Within three years of receiving
conditional approval, the sponsor would be required to submit a
biologics license application based on the accrued data of actual
use.197
4. The REGROW Act
In March 2016, Mark Kirk, a Republican senator from Illinois,
introduced a bill entitled, “Reliable and Effective Growth for
Regenerative Health Options that Improve Wellness” or the
“REGROW” Act.198 In his press release announcing the REGROW
Act, Senator Kirk stated that the bill “builds on [the December 2015
Bipartisan Policy Center report].”199 The bill ultimately died,200 but
offers another example of a reform proposal.
Under the REGROW Act, the FDA would have been required to
establish a program to “conditionally approve” certain regenerative
medicine therapies that demonstrated safety and a “reasonable
expectation of effectiveness.”201 Importantly, Phase 3 clinical trials
would not be required for those therapies before they became
(B) more-than-minimally manipulated but where processing does not alter the cells’ or tissues’ relevant
biological characteristics or function; or (2) (A) intended for non-homologous use that helps perform or
restore function in the recipient (“to reflect attributes of stem cells to differentiate and co-opt biological
processes to restore the cells/tissue into which they are placed”) and (B) either minimally-manipulated
or more-than-minimally manipulated but where processing does not alter the cells’ or tissues’ relevant
biological characteristics or function. Id. Therapies that fall into this category include autologous
culture-expanded adipose mesenchymal stem cells for subcutaneous injection, autologous adipose
stromal vascular fraction to reduce arthritic inflammation in joints, and allogeneic or autologous bone
marrow or cord tissue-derived mesenchymal stem cells for treatment of acute ischemic heart attack. Id.
195. Id. at 13.
196. Id.
197. Id.
198. S. 2689, 114th Cong. (2016). An identical bill, H.R. 4762, was introduced in the House by
Representative Mike Coffman, R-CO. H.R. 4762, 114th Cong. (2016).
199. Press Release, supra note 172; see also Cade Hildreth, Kirk, Manchin, Collins Introduce Bill to
Speed Development of Regenerative Medicine, BIOINFORMANT (Mar. 16, 2016),
https://www.bioinformant.com/kirk-manchin-collins-introduce-bill-to-speed-development-ofregenerative-medicine/#more-5609 [http://perma.cc/GVY5-4JRZ].
200. See S. 2689 – REGROW Act, supra note 169.
201. S. 2689, 114th Cong. § (2)(b) (2016).

https://readingroom.law.gsu.edu/gsulr/vol34/iss3/3

34

Duranske: Reforming Regenerative Medicine Regulation

2018]

REFORMING REGENERATIVE MEDICINE REGULATION

665

available to patients.202 To be eligible, products would also have to:
(1) not provoke an unintended immune response; (2) not be
genetically modified; and (3) be exclusively for a use that performs,
or helps achieve or restore, the same or similar function in the
recipient as in the donor.203 Within five years after conditional
approval, the therapy’s sponsor would be required to apply for the
therapy’s approval as a biologic.204 The only proposed limitation on
patient access would require informing patients receiving the
conditionally approved therapy of the therapy’s conditional status.205
None of these proposals strikes an appropriate balance between
access and risk because none require two necessary elements: (1)
significant evidence of safety and effectiveness, and (2) meaningful
measures to control the product’s diffusion.
B. Theorizing Adaptive Licensing
Adaptive licensing is an example of adaptive management, a
regulatory reform model that envisions administrative agencies
making iterative decisions instead of a single “grand decision.”206
Adaptive management responds to criticism that agency decisionmaking is overly focused on front-end analysis that must be
conducted and concluded prior to finalizing a regulatory decision.207
Such focus, critics charge, requires agency decision-makers to falsely
assume that they can predict the market and nonmarket effects of
their decisions, and leads to regulatory ossification and
inflexibility.208 Adaptive management responds by proposing an
202. Id.
203. Id. § (2)(b)(2)–(5).
204. Id. § (2)(b).
205. Id. § (2)(c).
206. Robin Kundis Craig & J.B. Ruhl, Designing Administrative Law for Adaptive Management, 67
VAND. L. REV. 1, 7 (2014).
207. Id.
208. See, e.g., Thomas O. McGarity, Some Thoughts on “Deossifying” the Rulemaking Process, 41
DUKE L.J. 1385, 1392 (1992); J.B. Ruhl & James Salzman, Mozart and the Red Queen: The Problem of
Regulatory Accretion in the Administrative State, 91 GEO. L.J. 757, 841 (2003) (addressing the problem
of regulatory accretion); Mark Seidenfeld, Bending the Rules: Flexible Regulation and Constraints on
Agency Discretion, 51 ADMIN. L. REV. 429, 457 (evaluating impact of ex ante restraints on agency
decision-making on predictability, accountability, and flexibility); Richard B. Steward, Administrative
Law in the Twenty-First Century, 78 N.Y.U. L. REV. 437, 447 (2003) (identifying inflexibility and rapid
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iterative process by which an administrative agency decides a
regulatory outcome through a multistep process that includes
defining the problem, identifying goals and options, implementing
action, and monitoring and evaluating outcomes.209
Adaptive management was born from a concern that conventional
methods for natural resource management were at odds with the
dynamic nature of ecosystems.210 But the same principles can apply
in a variety of other regulatory situations. Professor Robin Kundis
Craig delineates three factors that suggest when adaptive
management is appropriate: high uncertainty, high controllability,
and low risk.211 High uncertainty describes a decision-maker’s level
of understanding about how the regulatory context responds to
interventions.212 As uncertainty rises, confidence in a front-end
model of decision-making erodes, and adaptive management
becomes more appropriate.213 High controllability is the degree to
which a decision-maker can manipulate the regulatory
environment.214 Higher controllability means that the decision-maker
has a greater capacity to intervene in the problem and can engage in
more experimentation and option testing.215 Low risk describes the
chance that experimentation or interventions can lead to irreversible
adverse consequences. High risk makes adaptive management less
appropriate.216
Under this rubric, adaptive licensing is appropriate for regenerative
medicine therapies under the first principle of high uncertainty. But
the second and third principles of high controllability and low risk
highlight the flaws with applying adaptive licensing to regenerative
medicine therapies. Limits to the FDA’s authority, challenges with
implementation, and concerns with shortcutting premarket evidence
obsolescence as problems of command-and-control regulation).
209. Kundis Craig & Ruhl, supra note 206, at 7.
210. Id. at 17.
211. Id. at 19. An optional fourth factor, “dynamic system,” is not applicable to the drug approval
regime, so I have omitted it from my discussion.
212. Id.
213. Id.
214. Id.
215. Kundis Craig & Ruhl, supra note 206, at 19.
216. Id.

https://readingroom.law.gsu.edu/gsulr/vol34/iss3/3

36

Duranske: Reforming Regenerative Medicine Regulation

2018]

REFORMING REGENERATIVE MEDICINE REGULATION

667

generation are sufficiently serious to limit the appeal of such an
approach.
1. High Uncertainty
The first principle for adaptive management is that the regulatory
situation involves uncertainty.217 An approval decision for
regenerative medicine therapies will often involve uncertainty,
particularly if a therapy is biologically complex, is difficult to define
or characterize, or requires long-term evaluation of risk or efficacy.
First, regenerative medicine therapies present approval challenges
due to the presence of living cells.218 Biologics contain thousands to
millions of atoms formed into intricate designs.219 Because the
behavior of a cell depends on its microenvironment, changing the
cell’s micro-environment from a laboratory setting to an animal
model to a human means that the cells are exposed to different
factors in each setting.220 This complicates safety and efficacy studies
because the conditions in the laboratory may not accurately mimic
the cell’s environment in a human.221 Furthermore, once transplanted
into a human, the cells may change over time.222 Cells may
differentiate into unwanted cell types.223 They might also develop
unwanted functions; for example, cardiomyocyte-like cells could
generate electrical activity that is not coordinated with the rest of the
217. Id. at 19.
218. Although most do, not all regenerative medicine therapies use living cells. For example, the
bioengineered blood vessel marketed by Humacyte does not contain living cells. See, e.g., Abigail Xie,
Bioengineered Blood Vessels Shown to be Effective in Patients with Kidney Failure, CHRONICLE (May
26, 2016), http://www.dukechronicle.com/article/2016/05/bioengineered-blood-vessels-shown-to-beeffective-in-patients-with-kidney-failure [http://perma.cc/RQ4S-34XE].
219. Robin Feldman, Regulatory Property: The New IP, 40 COLUM. J. L. & ARTS 53, 82 (2016)
(citing Bryan Liang, Regulating Follow-On Biologics, 44 HARV. J. ON LEGIS. 363, 369 (2007)); Robert
N. Sahr, The Biologics Price Competition and Innovation Act: Innovation Must Come Before Price
Competition, B.C. INTELL. PROP. & TECH. F., July 19, 2009, at 2.
220. The Committee for Advanced Therapies (CAT) & the CAT Scientific Secretariat, supra note 36,
at 196–97.
221. Id.; Melissa K. Carpenter et al., Developing Safe Therapies from Human Pluripotent Stem Cells,
27 NATURE BIOTECHNOLOGY 606, 609 (2009).
222. U.S. FOOD & DRUG ADMIN., CONSIDERATIONS FOR THE DESIGN ON EARLY-PHASE CLINICAL
TRIALS OF CELLULAR AND GENE THERAPY PRODUCTS: GUIDANCE FOR INDUSTRY 4 (2015) [hereinafter
EARLY-PHASE: GUIDANCE].
223. Id.
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heart.224 Similarly, cells may migrate to an unintended location
within the recipient’s body.225
A second related problem is the heterogeneous nature of many
regenerative medicine products; they contain a variety of cell types,
with one or more being the “active agent.”226 Because defining and
controlling a product is essential for assessing a product’s safety and
efficacy, products with multiple living cell types that respond to their
environment—and are therefore in flux—challenge researchers’
abilities to properly characterize and control a product.227 Autologous
products that are uniquely sourced for each patient compound this
issue because of challenges in controlling lot-to-lot variability.228
Third, living cells’ unique characteristics may require regenerative
medicine therapies to undergo prohibitively long clinical trials to
demonstrate efficacy or to uncover risks.229 To be effective, a
regenerative therapy must repair the damaged tissue as intended.230
But the mechanism of action for tissue repair and regeneration is
often unknown and may be a result of cell secretions by the
transplanted cells rather than donor cell repopulation of the targeted
tissues.231 Given these unknowns, testing the therapy’s long-term
clinical outcome to determine whether the cells differentiated as
intended and then functionally repaired the damaged tissue can take a
long time—even several years.232 This length of time may make
clinical trials expensive and difficult because participants may be

224. Id.
225. Id.
226. Jeffrey L. Fox, FDA Scrutinizes Human Stem Cell Therapies, 26 NATURE BIOTECHNOLOGY 598,
599 (2008); Robert A. Preti, Bringing Safe and Effective Cell Therapies to the Bedside, 23 NATURE
BIOTECHNOLOGY 801, 801–02 (2005).
227. Fox, supra note 226, at 598.
228. EARLY-PHASE: GUIDANCE, supra note 222, at 5.
229. The Committee for Advanced Therapies (CAT) & the CAT Scientific Secretariat, supra note 36,
at 197.
230. Id.
231. Stefanie Dimmeler et al., Translational Strategies and Challenges in Regenerative Medicine, 20
NATURE MED. 814, 819 (2014).
232. The Committee for Advanced Therapies (CAT) & the CAT Scientific Secretariat, supra note 36,
at 197.
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unable to attend follow-up appointments or may die from their
underlying conditions or other causes.233
Uncovering risks may also be a long-term project. Stem cells that
are undifferentiated, or not completely differentiated, risk turning
into tumor cells.234 Pluripotent stem cells can produce teratomas,
which are an accumulation of many different cell types into a benign
tumor.235 These teratomas can fill anatomical space with potentially
disastrous consequences.236 They can also dedifferentiate and
develop into a malignant form.237 Although determining the
tumorigenicity of stem cells will be a main focus of preclinical
studies, clinical factors—such as the site of implantation and the
number of cells implanted—will impact a therapy’s tumorigenicity238
and will be a continued focus of long-term clinical trials.239
Adaptive licensing can address uncertainty by enabling regulators
and sponsors to design an approval pathway for a regenerative
medicine therapy that addresses its particular challenges. For
therapies that would take an inordinate amount of time to test in a
clinical trial, perhaps because the targeted condition is rare or
because the mechanism of action is slow-moving, an initial license
based on an unvalidated surrogate endpoint would allow limited early
patient access, followed by a subsequent lifting of restrictions based
on demonstrated success in meeting defined clinical endpoints.240 If
the concern is ensuring effectiveness in a real-world population, an
initial license might be based on an explanatory trial with closelymonitored inclusion criteria, and the postmarketing study would be a
pragmatic, randomly-controlled trial that evaluates effectiveness in a
real-world, clinical setting.241 If the concern is uncovering rare
233. Id.
234. Carpenter, supra note 221, at 610.
235. Fox, supra note 226, at 599.
236. Id.
237. Id.
238. Carpenter, supra note 221, at 610.
239. See Evgenios Neofytou et al., Hurdles to Clinical Translation of Human Induced Pluripotent
Stem Cells, 125 J. CLINICAL INVESTIGATION 2551, 2553 (2015); see also Amariglio, supra note 134, at
226 (describing diagnosis of brain tumor in boy four years after treatment with human fetal neural cells).
240. Eichler, supra note 77, at 431–32.
241. Id. at 430.
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adverse events, an initial license could be based on a randomlycontrolled trial, and the postmarket study could be a long-term
evaluation through observational studies or patient registries.242
2. High Controllability
The second principle for adaptive management advises high
controllability.243 Unlike the first principle of high uncertainty, which
is met in the regenerative medicine context, evidence of
controllability is less robust. Controllability in a regenerative
medicine scenario implicates four components: (1) the FDA’s
authority to approve biologics on the basis of less-robust evidence of
safety, purity, and potency; (2) the FDA’s authority to require
postmarketing studies from sponsors; (3) the FDA’s authority to
control the diffusion of the therapies; and (4) the FDA’s ability to
appropriately respond to new evidence.244 Regarding the first
component, the FDA does not have the authority to approve biologics
unless they are shown to be safe, pure, and potent.245 This limits, but
does not eliminate, the FDA’s current ability to approve biologics
that have not undertaken Phase 3 trials. Second, the FDA’s authority
to require postmarketing studies is limited to specific
circumstances.246 A broader grant of power is required if adaptive
licensing is pursued. Regarding the third component, the FDA has the
authority to control the diffusion of the product through its use of
242. See id. at 431–32; Gibson & Lemmens, supra note 168, at 207–08.
243. Craig & Rhule, supra note 206, at 19.
244. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY EXPEDITED PROGRAMS FOR SERIOUS
CONDITIONS–DRUGS AND BIOLOGICS 20 (2014) [hereinafter GUIDANCE FOR INDUSTRY EXPEDITED
PROGRAMS]; John D. Balian et al., Roadmap to Risk Evaluation and Mitigation Strategies (REMS)
Success, 1 THERAPEUTIC ADVANCES IN DRUG SAFETY 21, 21 (2010); Frequently Asked Questions About
Therapeutic Biological Products, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvala
pplications/therapeuticbiologicapplications/ucm113522.htm [https://perma.cc/CHV5 BD85] (last
updated July 7, 2015); Notice to Industry: Postmarketing Requirements–Postmarket Studies and
Clinical Trials, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ucm292758.htm
[https://perma.cc/TYV2-CTS8] (last updated Feb. 12, 2016) [hereinafter Notice to Industry:
Postmarketing Requirements].
245. Frequently Asked Questions About Therapeutic Biological Products, supra note 244.
246. Notice to Industry: Postmarketing Requirements, supra note 244.
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Risk Mitigation and Enforcement Measures (REMS).247 But the
fourth component, the ability to respond appropriately to new
evidence, will challenge the FDA for two distinct reasons: (1)
withdrawing a product from the marketplace—even if legally
possible—will be politically difficult, and (2) structuring an
agreement with a sponsor that is both flexible enough to respond to
new evidence yet certain enough to be attractive to sponsors may not
be feasible.
a. Approval Authority
As an initial matter, it is necessary to determine whether the FDA
has the authority to approve biologics on less robust evidence than is
traditional.248 Fundamentally, biologics may only be approved based
on evidence that demonstrates continued safety, purity, and
potency.249 Potency is interpreted to require effectiveness.250 Proof of
effectiveness generally requires adequate and well-controlled clinical
trials, unless either the FDA waives them as inapplicable or an
alternate method is adequate to substantiate effectiveness.251 One
such alternate method to substantiate effectiveness is the use of
validated surrogate endpoints. The existing RMAT and Accelerated
Approval pathways codify this understanding.252 But the FDA cannot
approve a therapy based on a body of evidence that fails to show that
the product is safe, pure, and potent.253 Such a move would simply
violate the FDA’s legal mandate to only approve a product where
existing evidence supports a conclusion of continued safety, purity,
and potency.

247. Balian et al., supra note 244, at 21.
248. GUIDANCE FOR INDUSTRY EXPEDITED PROGRAMS, supra note 244, at 10.
249. 42 U.S.C. § 262 (a)(2)(C)(i)(I) (Supp. 2017).
250. 21 C.F.R. § 600.3(5) (2012); U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY PROVIDING
CLINICAL EVIDENCE OF EFFECTIVENESS FOR HUMAN DRUGS AND BIOLOGICAL PRODUCTS 4 (1988).
251. 21 C.F.R. § 314.126 (a), (c), (e) (2002).
252. Peter Marks, This Is Not a Test: RMAT Designation Goes Live, U.S. FOOD & DRUG ADMIN.
(Mar. 21, 2017), https://blogs.fda.gov/fdavoice/index.php/2017/03/this-is-not-a-test-rmat-designationgoes-live/ [https://perma.cc/V84Y-9Z8B].
253. 42 U.S.C. § 262 (a)(2)(C).
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b. Postmarketing Authority
An adaptive licensing scheme also requires that sponsors agree to
postmarketing studies as a condition of earlier approval.254 This
second component raises an additional concern of insufficient
authority on the part of the FDA. The FDA only has clear statutory
authority to mandate postmarketing studies or trials based on safety
risks or accelerated approval. The Food and Drug Administration
Amendments Act of 2007 authorized the FDA to require the sponsor
of an approved biologic to conduct postmarketing studies or clinical
trials if the FDA became aware of new information about a serious
risk associated with the biologic since its approval.255 This authority
limits the FDA to requiring additional studies based only on safety
concerns, not on effectiveness concerns.256 The FDA also may
require sponsors to agree to conduct postmarketing studies as a
condition of receiving approval based on a surrogate or intermediate
endpoint.257 The pathways that enable the use of surrogate or
intermediate endpoints, Accelerated Approval and the RMAT
designation, are limited to therapies that are “intended to treat,
modify, reverse or cure a serious or life-threatening disease or
condition; and . . . have the potential to address unmet medical needs
for such a disease or condition.”258
But an adaptive licensing framework envisions accelerated
approval conditioned on postmarketing studies for a greater scope of
products than those covered by the FDA’s current statutory
254. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY POSTMARKETING STUDIES AND
CLINICAL TRIALS—IMPLEMENTATION OF SECTION 505(O)(3) OF THE FEDERAL FOOD, DRUG, AND
COSMETIC ACT 2–3 (2011) [hereinafter GUIDANCE FOR INDUSTRY POSTMARKETING STUDIES AND
CLINICAL TRIALS].
255. Food and Drug Administration Amendments of 2007, Public L. No. 110-85, § 901, 121 Stat. 823
(codified as 21 U.S.C. § 355(o)(3)(C)); 42 U.S.C. § 262(a)(2)(D) (Supp. 2016) (cross-referencing the
PHSA with the FDCA); GUIDANCE FOR INDUSTRY POSTMARKETING STUDIES AND CLINICAL TRIALS,
supra note 254, at 4, 16; see, e.g., Rebecca S. Eisenberg & W. Nicholson Price II, Promoting
Healthcare Innovation on the Demand Side, 10 J. L. AND BIOSCIENCES 3, 10–13 (2017); Riley, supra
note 17, at 458–60, (discussing postmarketing provisions of FDAAA).
256. Riley, supra note 17, at 465–66.
257. 21 U.S.C. § 356(g)(5) (Supp. 2016); Kenneth A. Oye et al., Legal Foundations of Adaptive
Licensing, 94 CLINICAL PHARMACOLOGY & THERAPEUTICS 309, 310 (2013).
258. 21 U.S.C. § 356(g)(2)(B–C). The limitations for accelerated approval of drugs or biologics are
substantively the same. See id. § 356(c)(2)–(3).
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authority.259 In such a situation, where the FDA seeks to impose
postmarketing requirements outside of its statutory permissions for
safety issues and accelerated pathways, the FDA’s authority is
murky. The FDA regularly requests that sponsors conduct
postmarketing studies, and sponsors commit in writing to the FDA to
conduct such postmarketing commitments.260 But the FDA does not
have clear authority to condition approval on “voluntary”
postmarketing studies.261
The biologics context can be analogized to Charles Steenburg’s
analysis of the new drug context.262 Significantly, the statute
governing the licensing of biologics is nondiscretionary: “a biologics
license shall be issued upon a determination . . . that the
establishment(s) and the product meet the applicable requirements
established in this chapter.”263 And such approval “shall constitute a
determination that the establishment(s) and the product meet
applicable requirements to ensure the continued safety, purity, and
potency of such products.”264 Thus, any requirement on the part of
the FDA to require postmarketing studies as a condition of approval
would lead to an incongruous result. Namely, the FDA would either
(1) implicitly admit that its approval did not constitute a
determination that the product meets the requirements to ensure
continued safety, purity, and potency of such product, or (2) deny the
sponsor its statutory right to receive premarketing approval for a
biologic which has met the applicable statutory requirements.265
In summary, combining the sources of FDA authority for approval
and postmarketing studies reveals a gap where the FDA does not
currently have the ability to approve products that have not been
shown to be safe, pure, and potent, or to require postmarketing
259. See Steenburg, supra note 81, at 361.
260. U.S. FOOD & DRUG ADMIN., REPORT TO CONGRESS, REPORTS ON POSTMARKETING STUDIES,
FDAMA 130, at 1 (2001); Steenburg, supra note 81, at 335–36.
261. See Steenburg, supra note 81, at 357.
262. Id. at 349 (arguing that the FDA’s authority to condition approval of new drugs on “voluntary”
commitments to conduct postmarketing studies conflicts with the FDA’s nondiscretionary mandate to
approve new drugs that meet the requirements of section 505(e)).
263. 21 C.F.R § 601.4 (2016) (emphasis added).
264. 21 C.F.R § 601.2(d).
265. See Steenburg, supra note 81, at 358.
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studies for regenerative medicine products that neither are subject to
approval under a fast-track pathway nor raise new safety concerns.
To implement a cohesive adaptive licensing scheme, it would
therefore be necessary for Congress to grant the FDA authority to
require postmarketing studies as a condition of earlier approval for
those products neither designated as RMATs (or otherwise reviewed
under a fast-track procedure) nor for which safety evidence supports
requiring postmarketing obligations.
c. Controlling Diffusion
The third component of controlling the regulatory environment
involves the FDA’s ability to control the diffusion of a regenerative
medicine therapy in the marketplace.266 This would allow regulators
to limit initial access to patients with the most appropriate
risk/benefit characteristics.267 Particularly for regenerative therapies
that have not been previously approved for use in humans, controls
would be needed to limit access until significant uncertainties are
resolved.268 Numerous methods exist to control diffusion, including
limiting use of the therapy to certain patient populations, restricting
off-label prescribing, and ensuring that prescribers and pharmacists
have received advanced certification. The FDA has the authority to
require such controls under its power to require sponsors to develop
and implement REMS, including Elements to Assure Safe Use
(ETASU). 269 These include requiring that:


health care providers have particular training
or experience, or are specially certified;

266. Turner & Knoepfler, supra note 23, at 156.
267. Eichler, supra note 77, at 429; Caplan & West, supra note 177, at 562.
268. R. Alta Charo, Speed Versus Safety in Drug Development, in FDA IN THE 21ST CENTURY: THE
CHALLENGES OF REGULATING DRUGS AND NEW TECHNOLOGIES 251, 263 (I. Glenn Cohen & Holly F.
Lynch, eds., 2015); Efthimios Parasidis, FDA’s Public Health Imperative: An Increased Role for
Postmarket Analysis, in FDA IN THE 21ST CENTURY: THE CHALLENGES OF REGULATING DRUGS AND
NEW TECHNOLOGIES 286, 293 (I. Glenn Cohen & Holly F. Lynch, eds., 2015).
269. The Public Health Service Act provides that license applications for biological products are
subject to the REMS provisions of the FDCA. 42 U.S.C. § 262(a)(2)(D) (Supp. 2017).
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pharmacies, practitioners, or health care
settings that dispense the therapy are specially
certified;
the therapy be dispensed to patients only in
certain health care settings;
the therapy be dispensed to patients with
evidence or other documentation of safe-use
conditions, such as laboratory results;
patients be subject to certain monitoring; or
patients be enrolled in a registry.270

Use of these elements would enable the FDA and sponsors to
control the diffusion of a regenerative medicine therapy while
continuing postmarket studies to further evaluate safety and
effectiveness.
d. Responding to Evidence
The fourth component of controlling the regulatory environment is
the FDA’s ability to react and respond to new evidence generated in
postmarketing trials and studies.271 Adaptive licensing frameworks
envision that postmarketing studies will generate evidence to support
either eliminating the risk mitigation measures or removing the
therapy from the market in the event that safety or efficacy issues
arise.272 Just like the many drugs that look promising in Phase 2 trials
but fail Phase 3 trials due to safety or efficacy problems,273 it is likely
270. Id. § (f)(3). Although the statute limits the FDA requiring ETASU for drugs “shown to meet the
standard” of safety and efficacy, the application of ETASU on drugs approved under the accelerated
approval pathway based on surrogate endpoints suggest that “effective” is liberally interpreted to apply
to all drugs approved by the FDA (which are, tautologically, safe and effective). Id.
271. Steenburg, supra note 81, at 320.
272. See Gibson & Lemmens, supra note 168, at 214–15.
273. A recent study published in Nature Biotechnology surveyed the drug development success rates
for over 7,000 drugs from 2003 to 2011. The authors demonstrated that only half of drug indications in
Phase 3 trials ultimately received approval from the FDA. Michael Hay et al., Clinical Development
Success Rates for Investigational Drugs, 32 NATURE BIOTECHNOLOGY 40, 44 (2014); U.S. FOOD &
DRUG ADMIN., 22 CASE STUDIES WHERE PHASE 2 AND PHASE 3 TRIALS HAD DIVERGENT RESULTS
(2017); see also ISSCR Opposes the REGROW Act, INT’L SOC’Y FOR STEM CELL RES. (Sept. 15, 2016),
http://www.isscr.org/professional-resources/news-publicationsss/isscr-news-articles/articlelisting/2016/09/15/isscr-opposes-the-regrow-act [https://perma.cc/H4RQ-NUJ9] (stating that as many as
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that if the FDA approved therapies under an adaptive licensing
scheme based on less rigorous evidence, those therapies would
similarly demonstrate a lack of safety or efficacy in postmarketing
studies. This suggests that an adaptive licensing framework would
require the FDA to have a robust ability to respond to safety or
effectiveness concerns. Current, its ability is mixed.
The FDA has authority to respond to sponsor failures to complete
REMS or mandatory postmarketing commitments. Under the relevant
statutes, a sponsor that fails to abide by a REMS or fails to conduct a
postmarketing study may not introduce the drug into interstate
commerce.274 Doing so would constitute a misbranding violation,
which could result in product seizures.275 The FDA also has the
authority to react to evidence that a product is not safe or effective.276
The biologics regulations also provide that the FDA can withdraw a
license in the event the product is not safe and effective for its
intended uses, or is misbranded with respect to any such use.277
But the FDA is subject to political pressures as well. Once a new
therapy is on the market, it likely will be politically difficult to
withdraw it, even if safety and efficacy concerns arise.278 Sponsors of
drug trials have been very successful in motivating grassroots support
for potential therapies, and the lobbying power of the biologics and
pharmaceutical industry raises concerns that regulators will be unable
to avoid industry capture.279
Finally, creating an agreement that both allows for the FDA to
react to new evidence and is sufficiently attractive to a product
sponsor will likely prove difficult. From the perspective of a drug
sponsor, participating in adaptive licensing involves a trade-off
40% of drug and biotechnology products that enter Phase 3 fail).
274. 21 U.S.C. § 355(p)(1)-(2) (Supp. 2016).
275. 21 U.S.C. § 355(d); 21 U.S.C. § 334 (2011). Compare United States v. Sandoz Pharm. Corp.,
894 F.2d 825, 826 (6th Cir. 1990) (upholding seizure where the defendant failed to file a new drug
application before introducing product into interstate commerce), with United States v. 225 Cartons, 687
F. Supp. 946, 962 (D. N.J. 1988) (upholding seizure of drugs where new drug application had not been
filed with FDA pursuant to 21 U.S.C. § 355), aff'd, 871 F.2d 409 (3d Cir. 1989).
276. 21 U.S.C. § 355(d).
277. 21 C.F.R. § 601.5(b)(vi) (2017).
278. Gibson & Lemmens, supra note 168, at 216–17.
279. See Overcoming Premarket Syndrome, supra note 81, at 275.
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between rules that are certain—even if not ideal—and rules that are
flexible but uncertain.280 For sponsors, the benefit of adaptive
licensing is earlier access to the market.281 But market forces could
dampen this benefit. If payors refuse to cover a therapy, the sponsor
would lose this prospective benefit.282 Similarly, even if payors agree
to cover the therapy, an overly-restricted pool of patients would
lessen the financial benefits to sponsors, a problem that could be
compounded by FDA-enforced market exclusivities. Because the
FDA grants a new biologic twelve years of marketing exclusivity, a
limit on the sponsor’s ability to receive payment for a product during
this period would act as a significant disincentive to participate in
adaptive licensing.283 Furthermore, if there is significant uncertainty
about how the FDA will respond to newly created evidence, such as
what type and length of studies will be needed to lift restrictions,
sponsors may decline to participate.284
The analysis of controllability reveals flaws in the application of
adaptive licensing to regenerative medicine therapies under the
FDA’s current authority. But even assuming that Congress granted
additional authority for proper implementation of an adaptive
licensing framework, a robust agreement between the therapy’s
sponsor, the FDA—and potentially payors—would be required to
properly incentivize sponsor participation. The fatal flaw with all
regenerative medicine adaptive licensing proposals, however, is the
absence of low risk.
3. Low Risk
The third principle for adaptive management, low risk, is not met
by adaptive licensing of regenerative medicine therapies. Given the
diversity of regenerative medicine therapies, they array widely across
a measure of risk. But for many therapies, early approval increases

280.
281.
282.
283.
284.
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the risk that patients will either incur opportunity costs if the therapy
does not work or suffer physical harms previously undiscovered.285
Most biologics that are investigated in clinical trials do not work.
A 2016 study of clinical development success rates over ten years,
from 2006 through 2015, involved almost 10,000 phase transitions
and found that only 11.5% of biologics that entered Phase 1 trials
ultimately received FDA approval.286 Of those biologics in Phase 3
trials, only half of them received FDA approval.287 Another study of
drug development success rates for over 7,000 drugs from 2003 to
2011 tells a similar story: only slightly more than half of biologics in
Phase 3 trials ultimately received FDA approval.288 This data is
important because it means that if regenerative medicine therapies
are provided to patients before Phase 3 trials are complete, we should
expect around half to fail to provide a benefit that outweighs the risk.
Such a system would make the initial patient population akin to a
class of clinical trial participants, but without the protections
provided by clinical trials.
Physical harm represents another risk. Although a product’s
REMS strategy could include measures to mitigate the likelihood of
harm—including communication tools such as distribution of a
medication guide,289 or communication by the sponsor to health care
providers of risks and mitigating measures—concerns remain.290
Current evidence about drugs and biologics approved under an
accelerated pathway suggest caution. Existing accelerated pathways
are similar to those suggested by adaptive licensing, and many
therapies that are approved under accelerated pathways based on
285. See Gibson & Lemmens, supra note 168, at 207.
286. DAVID W. THOMAS ET AL., CLINICAL DEVELOPMENT SUCCESS RATES 2006–2015, at 19–20
(2016).
287. Id.
288. Michael Hay et al., supra note 273, at 44; U.S. FOOD & DRUG ADMIN., supra note 273; see also
ISSCR Opposes the REGROW Act, supra note 273 (stating that as many as 40% of drug and
biotechnology products that enter Phase 3 fail).
289. 21 U.S.C. § 355-1(e)(2) (Supp. 2017). A medication guide highlights a safety concern and can
recommend mitigating measures such as weighing risks versus benefits, observing certain symptoms
that could prevent or mitigate a serious side effect, highlighting patient populations that are
contraindicated for the therapy, and stressing the importance of following the dosing regimen. 21 C.F.R.
§ 208.20 (2008).
290. 21 U.S.C. § 355-1(e)(2)-(3); Eichler, supra note 77, at 429.
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surrogate or intermediate endpoints fail to demonstrate the desired
ultimate clinical benefit.291
Two studies published in 2017 demonstrate the extent of the
problem. Dr. Aaron Kesselheim and his colleagues published a study
that showed that the medicines approved under expedited regulatory
pathways had a 38% higher rate of safety changes to product labels
than those approved under a traditional pathway.292 The expedited
drugs also had a 48% higher rate of changes to black box warnings,
which are warnings designed to disclose serious or life-threatening
risks, or contraindications.293 Another study found that nearly one in
three drugs approved by the FDA have safety issues after approval,
and the percentage is even higher for biologics and medicines
approved under an accelerated pathway.294
The use of surrogate endpoints is partly to blame. Although
surrogate endpoints allow sponsors to reduce the size, time, and cost
of clinical trials,295 they also pose challenges. A baseline challenge is
identifying those surrogate endpoints that ultimately demonstrate the
desired clinical benefit. Correlation does not equal causation, and
there is a risk that a beneficial change in a surrogate endpoint will not
necessarily cause a benefit in a clinical endpoint.296 For example, a
291. An intermediate clinical endpoint is a “clinical endpoint that can be measured earlier than
irreversible morbidity or mortality.” 21 U.S.C. § 356(c)(1)(A). A “surrogate endpoint” is a biomarker
that is intended to substitute for a clinical endpoint. INST. OF MED., EVALUATION OF BIOMARKERS AND
SURROGATE ENDPOINTS IN CHRONIC DISEASE 3 (Christine M. Michael & John R. Ball, eds., 2010),
https://www.nap.edu/read/12869/chapter/2#3 [https://perma.cc/ZNG9-YXEN] [hereinafter IOM,
BIOMARKERS]. Intermediate or surrogate endpoints include measures such as imaging data or markers in
the blood that predict, but do not prove, ultimate endpoints. Kelly Servick, Under 21st Century Cures
Legislation, Stem Cell Advocates Expect Regulatory Shortcuts, SCIENCE MAG., AAAS (Dec. 12, 2016,
2:45 PM) http://www.sciencemag.org/news/2016/12/under-21st-century-cures-legislation-stem-celladvocates-expect-regulatory-shortcuts-0 [https://perma.cc/Z95R-6QN6]. An example of a surrogate
endpoint is blood pressure in a trial for antihypertensive drugs. IOM, BIOMARKERS, supra, at 3 box S-2.
292. Aaron Kesselheim, Sana R. Mostaghim & Joshua J. Gagne, Safety Related Label Changes for
New Drugs After Approval in the US through Expedited Regulatory Pathways: Retrospective Cohort
Study, 358 BMJ 1 (2017); Ed Silverman, Speedy FDA Drug Reviews Also Yield More Safety Changes to
Labeling, STAT (Sept. 14, 2017), https://www.statnews.com/pharmalot/2017/09/14/fda-drug-reviewssafety-changes/ [https://perma.cc/MTP8-HJDJ].
293. Kesselheim, Mostaghim & Gagne, supra note 292; Silverman, supra note 292.
294. See generally Nicholas S. Downing et al., Postmarket Safety Events Among Novel Therapeutics
Approved by the US Food and Drug Administration Between 2001 and 2010, 317 JAMA 1854 (2017).
295. Behnood Bikdeli et al., Two Decades of Cardiovascular Trials with Primary Surrogate
Endpoints: 1990–2011, 116 J. AM. HEART ASS’N 1, 1 (2017).
296. Eugene J. Sullivan, Chief Med. Officer, United Therapeutics and Lung Rx, Presentation at the
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recent study of 220 cardiovascular clinical trials using surrogate
endpoints found that although over 70% of the trials demonstrated
the positive surrogate endpoint, only slightly more than a quarter
were followed with a clinical trial testing the clinical endpoint.297
And of these trials testing the clinical endpoint, nearly half failed to
demonstrate the clinical endpoint predicted by the surrogate
endpoint.298 The authors concluded that their findings “raise concern
about the certainty of assuming efficacy based on surrogate
endpoints. Even if used for approval of therapies in urgent situations,
postmarketing outcome trials are necessary.”299
These studies show that determining the true risk/benefit ratio of a
regenerative medicine therapy based on studies with surrogate or
intermediate clinical endpoints is less certain, because both the
benefit and the risk may not be as fully explored in a trial that looks
only at surrogate or intermediate clinical endpoints. The benefit must
be extrapolated from the observed surrogate effect; the risks may not
all be revealed in shorter, smaller studies.300
The existing challenges facing biologics in Phase 3 trials or under
current accelerated pathways should give us pause before expanding
the number of products approved based on early-stage clinical
evidence. The regulatory system must acknowledge the trade-offs
between faster access and safety. And until the expedited clinical trial
process is better able to predict harms, limiting expedited review to
those treatments that seek to address life-threatening conditions or
unmet medical needs reflects a more reasonable balance between the
FDA’s goals of protecting public health and advancing beneficial
innovation.

FDA’s 2013 Clinical Investigator Training Course: Clinical Trial Endpoints (Nov. 12, 2013),
http://www.fda.gov/downloads/Training/ClinicalInvestigatorTrainingCourse/UCM283378.pdf
[https://perma.cc/FCS3-WJGT].
297. Bikdeli et al., supra note 295, at 3.
298. Id.
299. Id. at 7.
300. Sullivan, supra note 296.
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4. A Question of Timing?
The principles of adaptive regulation contain an implicit fourth
requirement: that the principles align at an opportune time for reform.
In this sense, adaptive licensing may simply be an idea whose time
has not yet come. Many of the roadblocks discussed in the previous
section are surmountable. Where the FDA lacks authority, Congress
can grant it. Sponsors and the FDA can negotiate, test, and revise
their agreements. Concerns with payors can be worked through with
input from affected parties.
But the safety concerns remain. With time, however, these
roadblocks may also be surmountable. As regulatory science
advances and coincides with a deeper understanding of how
regenerative medicine therapies work, it may be possible to validate
new surrogate endpoints or harness electronic health records in a way
that offers greater assurances of safety and efficacy. The accelerated
approval pathways, including RMAT designation, provide a
laboratory for experimentation with the sources and content of data to
improve the predictive ability of early safety and efficacy data. And
this, in itself, is a form of adaptive management: defining the
problem that early-stage trial data does not sufficiently predict later
health and safety concerns, setting a goal to improve the data’s
predictive power, implementing various regulatory tools, and
evaluating each for success.
If we reach this goal, it will be worth revisiting adaptive licensing.
But until that hypothetical opportune moment, implementing
adaptive licensing for regenerative medicine therapies is unworkable
and unwise for a variety of reasons, including:
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Insufficient or unclear FDA authority to approve
biologics based on evidence that does not support
the continued safety, purity, and potency of the
product (except for products approved under
Congressionally-authorized accelerated pathways);
Insufficient or unclear authority of the FDA to
require postmarketing obligations for regenerative
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medicine products regulated as biologics (except for
new safety issues or under a Congressionallyauthorized accelerated pathway);
Political difficulties in removing products from the
marketplace, especially if based on a sponsor’s
violation of protocol as opposed to newlydiscovered safety or effectiveness issues;
Hurdles to incentivizing sponsor participation,
especially involving payment; and
Risks to patients who receive regenerative medicine
therapies that have not undergone thorough Phase 3
testing.

Given these impediments and challenges, the benefits derived from
adaptive licensing do not outweigh the risks to patients and the costs
of reform.
IV. Incremental Changes to Existing Regulations: Reform of Section
361 Products
In the previous section, I argued against adopting adaptive
licensing for those regenerative medicine products regulated as
biologics. In this section, I recommend reforming regenerative
medicine therapies regulated as section 361 products by expanding
the same surgical procedure exception and expanding the scope of
section 361. Whereas the reform proposals for biologics were
dramatic and would involve congressional action, FDA rulemaking,
and a fundamental change in the meaning of premarket approval, the
proposed reforms to the regulation of section 361 products are more
modest. The proposals simply involve updating the interpretation of
key statutory terms based on evolving scientific understanding.
A. FDA’s Guidance on Section 361 Products
Because the FDA’s regulatory requirements are most burdensome
for regenerative medicine therapies regulated as biologics,
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manufacturers often seek to have their products categorized into the
lowest or middle regulatory tier.301 To this end, manufacturers
recently asked the FDA to clarify certain section 361 requirements,
and the FDA responded by issuing guidance documents302 to explain
the FDA’s positions on the same surgical procedure exception;303 the
meaning of homologous use;304 the meaning of minimal
manipulation;305 and how the regulations apply to products derived
from adipose tissues.306
Although guidance documents are not legally binding, the FDA
issues them to communicate its expectations to the industry and to
stakeholders.307 Guidance documents assist the industry by providing
clarity and consistency.308 Under the Good Guidance Principles
adopted in 2000, the process for issuing a guidance document
requires the FDA to publish a draft guidance and notify the public of
its availability in hard copy and on the internet.309 The public is
invited to submit comments, and after a time, the FDA reviews the
comments and prepares a final draft that need not, but may as
appropriate, address the public’s comments.310 The draft guidances
contain a number of clarifications and explanations of the section 361
requirements.

301. CBER HCT/Ps Hearing, Sept. 12, 2016, supra note 149, at 69.
302. Id. at 9.
303. U.S. FOOD & DRUG ADMIN., SAME SURGICAL PROCEDURE EXCEPTION UNDER 21 C.F.R.
1271.15(B): QUESTIONS AND ANSWERS REGARDING THE SCOPE OF THE EXCEPTION: DRAFT GUIDANCE
FOR INDUSTRY (2014) [hereinafter FDA DRAFT GUIDANCE ON SAME SURGICAL PROCEDURE].
304. FDA DRAFT GUIDANCE ON HOMOLOGOUS USE, supra note 56.
305. FDA DRAFT GUIDANCE ON MINIMAL MANIPULATION, supra note 55.
306. U.S. FOOD & DRUG ADMIN., HUMAN CELLS, TISSUES, AND CELLULAR AND TISSUE BASED
PRODUCTS (HCT/PS) FROM ADIPOSE TISSUE: REGULATORY CONSIDERATIONS DRAFT GUIDANCE OF
INDUSTRY (2014) [hereinafter FDA DRAFT GUIDANCE ON ADIPOSE TISSUE].
307. See 21 C.F.R. § 10.115(d) (2012) (“Guidance documents do not establish legally enforceable
rights or responsibilities. They do not legally bind the public or FDA.”); id. § 10.115(g) (setting out
procedures for Level 1 guidance documents).
308. Erica Seiguer & John J. Smith, Perception and Process at the Food and Drug Administration:
Obligations and Trade-Offs in Rules and Guidances, 60 FOOD & DRUG L.J. 17, 30 (2005).
309. Id. at 21.
310. See 21 C.F.R. § 10.115.
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1. Same Surgical Procedure Draft Guidance
In this draft guidance, the FDA clarifies when a product is
excepted from the requirements applicable to section 361 products.
The exception is codified in section 1271.15(b): “You are not
required to comply with the requirements of this part if you are an
establishment that removes [cell or tissue products] from an
individual and implants such [cell or tissue products] into the same
individual during the same surgical procedure.”311 The guidance
clarifies that only a very limited number of steps may be performed
on the cells or tissues outside of the body to qualify for the same
surgical procedure exception. Specifically, the language of “such
[cell or tissue products]” means that the cell or tissue product can
only be “rinsed, cleaned, sized, or shaped.”312 Any other processing
will cause the manufacturer to lose the same surgical procedure
exception.313
The FDA’s rationale for limiting the scope of the exception rests
on the risk of infectious disease transmission.314 Steps taken when the
cells are processed, preserved, or removed from storage raise
contamination concerns beyond those typically associated with
surgery.315 Thus, any such steps require the manufacturer to follow
the requirements that apply to section 361 products or biologics.
2. Minimal Manipulation Draft Guidance
To qualify as a section 361 cell or tissue product, a product cannot
be more than minimally manipulated.316 The regulatory definition of
minimal manipulation depends on whether the therapy uses a
“structural tissue” or “cells or nonstructural tissue.”317 If the tissue is
structural, minimal manipulation is “processing that does not alter the
original relevant characteristics of the tissue relating to the tissue’s
311.
312.
313.
314.
315.
316.
317.

21 CFR § 1271.15(b) (emphasis added).
FDA DRAFT GUIDANCE ON SAME SURGICAL PROCEDURE, supra note 303, at 3 n.4.
Id. at 3.
Id.
Id. at 5.
Ravitz, Halpern & Leongini, supra note 54.
21 C.F.R. § 1271.3(f)(1)–(2) (2004).
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utility for reconstruction, repair, or replacement.”318 In nonstructural
tissue, minimal manipulation is “processing that does not alter the
relevant biological characteristics of cells or tissues.”319
The minimal manipulation draft guidance provides examples of
minimal manipulation and provides general principles for application
to other or future products.320 First, because the regulations set
different standards for minimal manipulation depending on whether
the tissue is structural or non-structural,321 the guidance clarifies
these terms. Structural tissue supports and serves “as a barrier or
conduit, or connect[s], cover[s], or cushion[s].”322 Examples of
structural tissue include bone, skin, blood vessels, adipose (fat)
tissue, articular cartilage, non-articular cartilage, and tendons or
ligaments.323 Nonstructural tissues are “those that serve
predominately metabolic or other biochemical roles in the body such
as hematopoietic, immune and endocrine functions,” and include
reproductive cells or tissues, cord blood, and pancreatic tissue, to
name a few.324
Second, the draft guidance explains the standards for minimal
manipulation by explaining and illustrating the foundational concepts
of (1) structural tissues’ original relevant characteristics relating to its
utility for reconstruction, repair, or replacement, and (2) nonstructural tissues’ relevant biological characteristics.325 For instance,
stem cells isolated from adipose tissue are more than minimally
manipulated.326 This is because, according to the FDA, fat is a
structural tissue, and its original relevant characteristics of padding
and cushioning are based on its bulk and lipid storage capacity.327
Processing for stem cell extraction breaks down and eliminates the

318.
319.
320.
321.
322.
323.
324.
325.
326.
327.
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Id. at § 1271.3(f)(1).
Id. at § 1271.3(f)(2).
FDA DRAFT GUIDANCE ON MINIMAL MANIPULATION, supra note 55, at 3, 5, 8.
Id. at 3.
Id. at 4.
Id. at 5.
Id. at 8.
Id. at 3.
FDA DRAFT GUIDANCE ON MINIMAL MANIPULATION, supra note 55, at 6.
Id. at 5–6.

55

Georgia State University Law Review, Vol. 34, Iss. 3 [2018], Art. 3

686

GEORGIA STATE UNIVERSITY LAW REVIEW

[Vol. 34:3

structural components that provide cushioning and support, so the
product is considered more than minimally manipulated.328
If a product is more than minimally manipulated, it loses section
361 status and is subject to regulation as a drug or biologic.329 The
rationale is that products that are more than minimally manipulated
have the potential to, or are intended to, change the cell or tissue’s
biological characteristics or functions, which raises concerns about
the product’s ultimate safety or effectiveness.330
3. Homologous Use Draft Guidance
A section 361 product must be intended for homologous use.331
This means that the cells or tissues in the recipient must perform the
same basic function in the recipient as in the donor.332 This
requirement addresses the concern that non-homologous uses raise
safety and effectiveness concerns due to the diminished basis on
which to predict the product’s behavior.333 The requirement applies
to both allogenic and autologous uses.334 In other words, there is no
exception to this requirement even when the tissue is taken from and
re-implanted into the same patient.335
The draft guidance clarifies terms and provides several examples.
When the tissue is used for the exact same purpose in the donor and
the recipient, the use is homologous; for example, a heart valve
transplanted to replace a recipient’s dysfunctional heart valve is a
homologous use.336 A use in the recipient that has the same basic
function as the use in the donor also qualifies.337 For example, the use
of a pericardium (the membrane around heart) as a wound covering
for defects of the dura mater (the membrane enveloping brain and
328. Id. at 8.
329. Id. at 2–3.
330. PROPOSED APPROACH TO REGULATION OF CELLULAR AND TISSUE-BASED PRODUCTS, supra note
48, at 9721.
331. 21 C.F.R. § 1271.10(a)(2) (2004).
332. Id. § 1271.3(c).
333. FDA DRAFT GUIDANCE ON HOMOLOGOUS USE, supra note 56, at 3.
334. Id. at 2.
335. See id.
336. Id. at 4.
337. Id.
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spinal cord) is a homologous use because it serves as a covering in
both its original form and in the recipient.338 Uses that are not the
same in the donor and recipient are not considered homologous.339
For example, because the basic function of hematopoietic stem cells
is to form and replenish the blood system, any use outside of this
purpose—like infusion to treat cerebral palsy—is not homologous.340
The FDA also clarifies that if the cell or tissue product is intended for
use as an unproven treatment for a myriad of diseases or conditions,
the use is not homologous.341
4. Adipose Tissue Products Draft Guidance
In this draft guidance, the FDA specifically explains the section
361 requirements as applied to products derived from adipose (fat)
tissue.342 Adipose tissue is the most common source of stem cells
used in unapproved stem cell therapies.343 The FDA “recently
received numerous inquiries regarding [cell or tissue products]
manufactured from adipose tissues.”344 In this draft guidance, the
FDA states that it generally considers adipose tissue to be a structural
tissue because it is a “connective tissue that stores energy in the form
of lipids, insulates the body, and provides cushioning and support for
subcutaneous tissues and internal organs.”345 It is composed
primarily of adipocyte cells, but also contains a number of other cell
types.346
The guidance applies the section 361 requirements to adipose
tissue. The FDA states that it considers adipose tissue more than
minimally manipulated when it is processed to isolate the non-fat
cells from the tissue.347 This means that the procedures stem cell
338.
339.
340.
341.
342.
343.
344.
345.
346.
347.
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See id. at 5.
See id. at 6.
FDA DRAFT GUIDANCE ON ADIPOSE TISSUE, supra note 306, at 1.
Turner & Knoepfler, supra note 23, at 156.
Id. at 2.
Id. at 1.
Id. at 1–2.
Id. at 3.
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clinics use to extract stem cells from adipose tissue are generally
considered more-than-minimal manipulation.348 In clarifying the
homologous use requirement, the draft guidance states that the FDA
would likely consider the use of adipose tissue as a cosmetic filler
homologous use because this use reflects a basic function of adipose
tissue: to support subcutaneous tissues.349 But the FDA would not
consider the use of the tissue to treat bone and joint disease a
homologous use because the tissue does not perform this function in
the donor.350
These examples demonstrate that the FDA does not consider the
products provided by stem cell clinics to meet the section 361
requirements of minimal manipulation and homologous use. The
stem cell clinics generally isolate the non-fat cells for implantation,
which the FDA defines as more than minimal manipulation.351 And
the clinics advertise the stem cell-derived products for functions
other than those traditionally performed by adipose tissue, which the
FDA interprets as non-homologous use.352
Furthermore, the draft guidance clarifies that the stem cell clinics’
products are unlikely to fall within the same surgical procedure
exception.353 This is because the exception considers cells to be the
same cells (as expressed in the regulation, “such [cell or tissue
products]”) only if they are rinsed and cleansed to remove debris.354
Because the stem cell clinics typically engage in additional steps such
as cell isolation, cell expansion, or enzymatic digestion, the products
are not covered under the same surgical procedure exception.355

348.
349.
350.
351.
352.
353.
354.
355.

Id. at 4.
FDA DRAFT GUIDANCE ON ADIPOSE TISSUE, supra note 306, at 5.
Id.
Id. at 6.
Id.
Id. at 8.
Id.
See FDA DRAFT GUIDANCE ON ADIPOSE TISSUE, supra note 306, at 8.
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B. Reforms to Expand the Scope of Section 361 and the Same
Surgical Procedure Exception
1. Treatment of Autologous Therapies
a. Existing Proposals Suggest Treating Autologous
Therapies as Exceptional
Several proposals for reform address the scope of section 361. A
common theme among these proposals is to treat therapies that use
the patient’s own cells as source material, an autologous use,
differently from those that use a donor’s cells. This distinction is
already partly captured in existing regulations: any use of cell or
tissue products that affects the body systemically or depends on cell
metabolism does not qualify for section 361 unless the cells come
from a donor (or a first- or second-degree relative).356 But reformers
want to see a greater distinction in the legal treatment of these uses.
Professor Mary Ann Chirba and attorney Stephanie Garfield have
argued that autologous therapies that are either developed or used by
practicing physicians should be exempt from regulation or,
alternatively, should be regulated under a more flexible framework
than therapies developed by pharmaceutical companies.357 Failure to
do so, they argued, will harm innovation, disrespect patient
autonomy, and hamper the public’s health.358 Attorney Greg Pivarnik
came to a similar conclusion but for a different reason. He argued
that although the FDA has the legal authority to regulate autologous
stem cell treatments, it should decline to do so.359 He reasoned that
the information asymmetry between pharmaceutical companies and
patients justified premarket approval for traditional drugs and
allogenic therapies, but that the personal doctor–patient relationship
assuages fears that patients will make uniformed choices.360
356. 21 C.F.R. § 1271.10 (2017).
357. Chirba & Garfield, supra note 109, at 253.
358. Id. at 268.
359. Greg Pivarnik, Cells as Drugs? Regulating the Future of Medicine, 40 AM. J. L. & MED. 298,
319 (2014).
360. Id.
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Furthermore, to the extent that doctors breach their duties to the
patient, Pivarnik argued, state regulations and tort laws effectively
address these concerns.361 Other commentators, however, have
disagreed and argued that autologous therapies should remain subject
to FDA oversight because of their risks of contamination and
infection.362 Professor Barbara von Tigerstrom noted unique
challenges with regulating autologous therapies, but argued that FDA
regulation is still needed to ensure that the therapies are safe and
effective.363
A more nuanced approach was offered by Jay Segal, chief
biotechnology officer and head of scientific strategy and policy for
Johnson & Johnson, during the FDA’s hearing.364 Segal argued that
the same surgical procedure exception should be applied more
broadly to include autologous cell products that were minimally
manipulated.365 The current regulations provide that only autologous
therapies that are rinsed, cleansed, sized, and shaped are covered by
the same surgery exception.366 Siegel argued that the current
distinction between these products and products that undergo other
“minimal” procedures, which are currently not allowed under the
same surgical procedure exception, is not sound based on the cell or
tissue product’s risk of contamination and transmission of infectious
diseases.367 Furthermore, he argued that existing regulations of
surgical facilities ensure that these facilities have procedures in place
to prevent the spread of communicable disease—so regulation of the
entities as manufacturers of section 361 products is unnecessary and
duplicative.368

361. Id. at 320.
362. See, e.g., Barbara von Tigerstrom, The Food and Drug Administration, Regenerative Sciences,
and the Regulation of Autologous Stem Cell Therapies, 66 FOOD & DRUG L.J. 479, 488, 502 (2011).
363. Id. at 504.
364. CBER HCT/Ps Hearing, Sept. 12, 2016, supra note 149, at 40.
365. Id. at 40–42.
366. Id. at 88–89.
367. Id. at 40–42, 88–89 (statement of Dr. Jay Siegel, chief biotechnology officer and head of
scientific strategy for Johnson & Johnson).
368. Id.
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b. Autologous Therapies Should Not All Be Exempt from
FDA Regulation, but Expansion of the Same Surgical
Procedure Exception Is Justified
Reform proposals that promote removing all autologous therapies
from FDA regulation are misguided. Under the current system, some
autologous therapies where the cells are only rinsed, cleansed, sized,
or shaped are exempt from FDA regulation;369 some where the cells
are not more than minimally manipulated and are for homologous use
are subject to the communicable disease regulations of section
361;370 and some that are more than minimally manipulated or not for
homologous use are subject to regulation as biologics.371 Working
backward from the most restrictive to the least restrictive levels of
regulation, it would be foolish to exempt all autologous regenerative
medicine therapies from regulation as biologics. When a cell-based
product is intended for a different purpose than the cells originally
placed in the body, or when the cells have been altered in a way that
affects their relevant characteristics, we do not know how the cells
will function in the recipient absent clinical evidence.372 And not
only might the autologous therapies not work, they might cause
physical harm.373 Former FDA Commissioner Robert Califf
described two instances in which autologous therapies likely caused
patient harms.374 In one instance, autologous hematopoietic stem
cells that were injected into a patient with kidney failure were
associated with the formation of tumors.375 In a separate instance,
autologous stem cells derived from adipose tissue and injected into
the eyes of three patients with macular degeneration were associated
with worsening vision in all three.376
Removing all autologous therapies from section 361 regulations is
also unwise. Minimal manipulation of cells—including banking,
369.
370.
371.
372.
373.
374.
375.
376.
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transporting, or processing—risks the transmission of communicable
disease because the products are susceptible to contamination or mixups.377 For example, an infected product could cross-contaminate
other products stored in the same liquid nitrogen in a freezer.
Similarly, a product could contaminate processing equipment.378 The
current Good Tissue Practice requirements that apply to all section
361 products set forth the procedures and controls to prevent such
contamination.379 Furthermore, it is not at all clear that the
regulations that govern hospitals and ambulatory surgical centers are
sufficient to guard against viral and bacterial contamination.380
On the other hand, the FDA may be able to expand the same
surgical procedure exception in some instances. For example, if
certain processing techniques involve more manipulation than
rinsing, cleansing, sizing, or shaping but do not increase the risk of
contamination, such processes could be captured under the same
surgical procedure exemption. For example, if the FDA determined
that a certain closed processing system, or storage in liquid nitrogen
vapors as opposed to the liquid, did not increase the risk of
contamination, such processing steps could be captured under the
same surgical procedure exception without compromising the
purpose of the exception.
2. Expanding the Scope of Section 361
A second path to speeding products to market is to allow more
therapies to qualify as section 361 products. This would permit the
377. PROPOSED APPROACH TO REGULATION OF CELLULAR AND TISSUE-BASED PRODUCTS, supra
note 48, at 12; cf. Poliana Alves Patah et al., Microbial Contamination of Hematopoietic Progenitor Cell
Products: Clinical Outcome, 40 BONE MARROW TRANSPLANTATION 365, 366 (2007).
378. PROPOSED APPROACH TO REGULATION OF CELLULAR AND TISSUE-BASED PRODUCTS, supra
note 48, at 12.
379. See U.S. FOOD & DRUG ADMIN., CURRENT GOOD TISSUE PRACTICE (CGTP) AND ADDITIONAL
REQUIREMENTS FOR MANUFACTURERS OF HUMAN CELLS, TISSUES, AND CELLULAR AND TISSUE-BASED
PRODUCTS (HCT/PS): GUIDANCE FOR INDUSTRY 12 (2011).
380. See, e.g., Laura Landro, The Informed Patient: At the Clinic, Care . . . and Infection, WALL
STREET J. (Oct. 25, 2011),
https://www.wsj.com/articles/SB10001424052970203911804576651243331232116
[https://perma.cc/63DR-TJZE] (reporting cases of dangerous transmissions of bacteria and viruses at
ambulatory surgical centers).

https://readingroom.law.gsu.edu/gsulr/vol34/iss3/3

62

Duranske: Reforming Regenerative Medicine Regulation

2018]

REFORMING REGENERATIVE MEDICINE REGULATION

693

manufacturers of these products to meet only the lighter requirements
of section 361: registering with the FDA and implementing
procedures to avoid contamination and the transmission of infectious
disease.381 Section 361 cell or tissue products avoid the lengthy
clinical trials required to prove safety and effectiveness, or purity and
potency, required for drugs and biological products.382 A
liberalization of section 361’s requirements could occur if the FDA
more loosely interpreted the homologous use and minimal
manipulation requirements. For example, the homologous use
requirement, as currently interpreted, states that adipose tissue used
to fill in the hollows of the cheeks is a homologous use, but the use of
the same tissue in breast reconstruction is not a homologous use. This
is because, as stated by the FDA, the “basic function of breast tissue
is to produce milk (lactation) after childbirth.”383 And, because
lactation is not a basic function of adipose tissue, such use would not
be covered under section 361.384 A more liberal interpretation might
allow for multiple basic function determinations of both the donated
and recipient tissues.385 Similarly, the FDA could soften the minimal
manipulation requirement. Currently, decellularization generally
renders adipose tissue more than minimally manipulated because it
alters its “original relevant characteristics” relating to its “utility for
reconstruction, repair, or replacement.”386 Because decellularization
removes adipose tissue’s bulk, it no longer provides cushioning and
support, which are its original relevant characteristics.387 But if the
FDA accepted other original relevant characteristics of adipose
tissue, such as its paracrine function, additional therapies would meet
the minimal manipulation requirement.388
381. Chirba & Garfield, supra note 109, at 251.
382. FDA DRAFT GUIDANCE ON ADIPOSE TISSUE, supra note 306, at 6.
383. Id. at 5.
384. Id.
385. See, e.g., CBER HCT/Ps Hearing, Sept. 12, 2016, supra note 149, at 112 (statement of Dr. Mary
Ann Chirba-Martin, professor of health law at Boston College Law School).
386. FDA DRAFT GUIDANCE ON ADIPOSE TISSUE, supra note 306, at 4; CBER HCT/Ps Hearing, Sept.
12, 2016, supra note 149, at 72–73.
387. FDA DRAFT GUIDANCE ON ADIPOSE TISSUE, supra note 306, at 1.
388. See CBER HCT/Ps Hearing, Sept. 12, 2016, supra note 149, at 115 (statement of Dr. Arnold
Caplan, professor at Case Western Reserve University) (“Fat in particular has an absolutely essential
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To the extent that a tissue or cell has multiple basic functions, the
FDA should expand the homologous use requirement. Similarly, to
the extent scientific evidence supports multiple original relevant
characteristics for cells or tissues, the FDA should expand the
minimal manipulation requirement. This will allow additional
products that do not raise drug-level safety and effectiveness
concerns to receive the lighter regulatory touch of section 361.
CONCLUSION
Reform is in the air. Industry representatives, patients and their
advocates, politicians, and regulators are analyzing and advocating
for changes to the regenerative medicine regulatory framework to
best address how to bring innovative therapies to patients while
avoiding common or foreseeable patient harms.
Significant reforms of the product approval framework for
regenerative medicine therapies regulated as biologics have been
proposed; they are impracticable and unwise. Existing proposals fall
short because they fail to address problems with the FDA’s authority,
implementation challenges, and most significantly, safety and
efficacy concerns. Continued study of lifecycle approaches, however,
is warranted, because advances in regulatory science and regenerative
medicine may enable the FDA to implement adaptive licensing with
greater assurances of safety and effectiveness.
For moderate-risk products, although proposals that drastically
expand the scope of products exempted from regulation are unwise,
more incremental proposals that expand the same surgical procedure
exception and the scope of products regulated under section 361 can
be implemented without damaging section 361’s underlying goals of
avoiding contamination and the transmission of infectious disease.
The current system is not broken. Harnessing the body’s ability to
heal itself and translating this understanding into clinical practice is
complicated and time-consuming, and the current framework already
paracrine activity as a tissue; and so, therefore, if you transplant or transfer fat from one tissue to
another, you’re taking advantage of its paracrine activities.”).
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provides regulatory flexibility depending on a therapy’s risks.
Implementing regulatory shortcuts that will risk harming patients is
not the answer, but neither is treating the current system as set in
stone. Instead, advances in scientific understanding warrant
incremental changes to the existing section 361 framework. And
although an overhaul of the biologics framework is premature,
advances in regulatory science and increased understanding of
regenerative medicine may one day justify such an undertaking.
The next few years will bring significant advances to the
regenerative medicine field, and its regulation must be flexible to
keep pace. Whether the reforms are incremental or more
transformative, measures taken now can ensure continued patient
protection while advancing access to therapies when it is safe and
appropriate.
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